
==== Front
Int J Mol SciInt J Mol SciijmsInternational Journal of Molecular Sciences1422-0067MDPI 10.3390/ijms20051149ijms-20-01149ReviewAn Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases Law Shi-Hui 1†Chan Mei-Lin 23†Marathe Gopal K. 4Parveen Farzana 1Chen Chu-Huang 2567https://orcid.org/0000-0002-2547-0987Ke Liang-Yin 1256*1 Department of Medical Laboratory Science and Biotechnology, College of Health Sciences, Kaohsiung Medical University, Kaohsiung 80708, Taiwan; shlaw_0909@hotmail.com (S.-H.L.); farzanaparveen@zoho.com (F.P.)2 Center for Lipid Biosciences, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan; mlchan127@gmail.com (M.-L.C.); cchen@texasheart.org (C.-H.C.)3 Division of Thoracic Surgery, Department of Surgery, MacKay Memorial Hospital, MacKay Medical College, Taipei 10449, Taiwan4 Department of Studies in Biochemistry, Manasagangothri, University of Mysore, Mysore 570006, India; marathe1962@gmail.com5 Lipid Science and Aging Research Center, Kaohsiung Medical University, Kaohsiung 80708, Taiwan6 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan7 Vascular and Medicinal Research, Texas Heart Institute, Houston, TX 77030, USA* Correspondence: kly@kmu.edu.tw; Tel.: +886-73121101 (ext. 2297); Fax: +886-73111996† These authors contributed equally.

06 3 2019 3 2019 20 5 114906 2 2019 28 2 2019 © 2019 by the authors.2019Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).Lysophosphatidylcholine (LPC) is increasingly recognized as a key marker/factor positively associated with cardiovascular and neurodegenerative diseases. However, findings from recent clinical lipidomic studies of LPC have been controversial. A key issue is the complexity of the enzymatic cascade involved in LPC metabolism. Here, we address the coordination of these enzymes and the derangement that may disrupt LPC homeostasis, leading to metabolic disorders. LPC is mainly derived from the turnover of phosphatidylcholine (PC) in the circulation by phospholipase A2 (PLA2). In the presence of Acyl-CoA, lysophosphatidylcholine acyltransferase (LPCAT) converts LPC to PC, which rapidly gets recycled by the Lands cycle. However, overexpression or enhanced activity of PLA2 increases the LPC content in modified low-density lipoprotein (LDL) and oxidized LDL, which play significant roles in the development of atherosclerotic plaques and endothelial dysfunction. The intracellular enzyme LPCAT cannot directly remove LPC from circulation. Hydrolysis of LPC by autotaxin, an enzyme with lysophospholipase D activity, generates lysophosphatidic acid, which is highly associated with cancers. Although enzymes with lysophospholipase A1 activity could theoretically degrade LPC into harmless metabolites, they have not been found in the circulation. In conclusion, understanding enzyme kinetics and LPC metabolism may help identify novel therapeutic targets in LPC-associated diseases.

lysophosphatidylcholinelipoprotein-associated phospholipase A2lysophosphatidylcholine acyltransferaselysophospholipase A1autotaxinG protein–coupled receptor G2A
==== Body
1. Introduction
1.1. General Features of Lysophosphatidylcholine
Lysophosphatidylcholine (LPC), also called lysolecithins, is a class of lipid biomolecule derived by the cleaving of phosphatidylcholine (PC) via the action of phospholipase A2 (PLA2) [1,2] and/or by the transfer of fatty acids to free cholesterol via lecithin-cholesterol acyltransferase (LCAT) [3]. In healthy individuals, the plasma level of LPC ranges from 125 to 143 nmole/mL, but its level increases in cardiovascular diseases, diabetes, ovarian cancer, and renal failure [4,5,6]. PC, also called lecithins (lécithine), was originally derived from the Greek word “lekithos” (λεκιθος, egg yolk), and in 1847, Theodore Nicolas Gobley [7] published a description of their chemical structure. PC is a major component of biological membranes found in animal and plant cells [8]. Although LPCs can be produced in the circulation when PLA2 cleaves PCs, they can be converted back to PCs by the enzyme lysophosphatidylcholine acyltransferase (LPCAT) in the presence of Acyl-CoA. These two pathways are part of the Lands cycle [9], which is one of the body’s mechanisms for the cyclical synthesis and degradation of PC. The details of these processes are described in this review. LPCATs are intracellular enzymes found in body tissues such as lung [10], liver [11], and adipose tissue [12], but these intracellular enzymes are unlikely to interact directly with extracellular circulating LPC, which is positively associated with diseases [4,5,6].

1.2. Effects of Lysophosphatidylcholines
In the liver, LPCs upregulate genes involved in cholesterol biosynthesis and downregulate genes involved in hepatic fatty acid oxidation [13]. Higher concentrations of LPCs disrupt mitochondrial integrity and enhance cytochrome C release in hepatocytes (Table 1). In the vascular system, LPC induces prolonged endothelial activation and atherogenesis [14,15]. It modulates inflammatory chemokine expression from endothelial cells [16,17,18,19], impairs arterial relaxation [20], increases oxidative stress [21,22], and inhibits endothelial cell migration and proliferation [23,24]. Rich in oxidized low-density lipoprotein (OxLDL), LPCs have been identified as a group of proinflammatory lipids that are critically involved in the pathogenesis of atherosclerosis [25] and other inflammatory diseases such as multiple sclerosis [26,27]. Overproduction of LPC can result from the overexpression or enhanced activity of enzymes such as lipoprotein-associated phospholipase A2 (Lp-PLA2) in circulation [28,29]. In contrast, effectively clearing LPC, through either Lands cycle remodeling inside cells or the direct degradation of circulating LPC, is essential for maintaining LPC levels.

1.3. Lysophosphatidylcholine Signaling through Receptors
LPC activates multiple signaling pathways that are involved in oxidative stress and inflammatory responses. The signaling cascade is triggered through G protein–coupled receptor G2A [30,31,32,33] and Toll-like receptors [34]. However, whether G2A is a canonical receptor for LPC is debated [35]. It is notable that LPC is not an agonist of the platelet-activating factor receptor, and the LPC used in previous studies may have been contaminated with PAF-like lipids [36]. Exogenous LPC induces pro-inflammatory effects such as upregulated gene expression for smooth muscle/fibroblast-directed growth factors and adhesion molecules in endothelial cells [37,38], increased release of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-α (TNF-α) from adipocytes [39,40], enhanced secretion of interferon-γ from peripheral blood mononuclear leucocytes [16], and increased activation of B cells [16] and macrophages [30,34,41]. In addition, LPC enhances the Foxp3 expression and suppressive function of naturally occurring regulatory T cells (nTregs) [42]; these actions are believed to be mediated through G2A signaling [42]. nTregs are responsible for preventing immune responses through various means, including the production of anti-inflammatory cytokines [43]. In 2014, researchers reported that LPC promotes and stabilizes macrophage polarization strongly toward the M1 phenotype, and that blocking the G2A receptor reduces the impact of LPC on macrophage polarization [44]. In the central nervous system, LPC induces demyelination in white matter of the spinal cord by activating G protein-coupled receptor 17 (Gpr17) signaling. Highly expressed in brain tissue, GPR17 reduces the intracellular cAMP level and induces pro-apoptotic gene XIAP-associated factor 1 (Xaf1) expression, which in turn inhibits oligodendrocyte survival and precursor cell differentiation [45]. In another study, LPC impaired the barrier function of the endothelium in the brain microvasculature and induced inflammation through G protein-coupled receptor4 (Gpr4) [46]. LPC mediates pericyte loss, vascular barrier disruption, demyelination, and motor function defects; all of these effects can be decreased by iloprost, an analog of prostacyclin [47]. The mechanism for demyelination involves the integration of LPC into the cell membrane, which induces permeability and necrotic cell death [48].

1.4. Recent Clinical Findings of Lysophosphatidylcholines
As described above, LPC may alter the physiology of the vascular endothelium, pericytes, and neuron cells in vitro and in vivo, indicating it may be a compelling risk factor and may be associated with the pathogenesis and prognosis of cardiovascular diseases. However, findings from recent clinical lipidomics studies have been controversial and somewhat confusing. For example, plasma LPCs showed an inverse relationship with cardiovascular diseases [51,52,53]. In other studies, the LPC:PC ratio decreased either in plasma or cerebrospinal fluid from patients with Alzheimer’s disease [54,55,56]. To help clarify the controversy and delineate the role of LPC in these diseases, we have provided a timely and important updated review on LPC homeostasis. In this article, we discuss whether excess LPC has a cause-effect association with human diseases. Specifically, we review LPC production in circulation and its transport and reconversion to PC within cells.

2. Lysophosphatidylcholine and Human Diseases
2.1. Lysophosphatidylcholine and Cardiovascular Diseases
Cardiovascular diseases are a class of diseases that include atherosclerosis, diabetes, metabolic syndrome, myocardial infarction, and angina. According to the World Health Organization, cardiovascular diseases account for 17.7 million deaths (31% of all global deaths) each year and are now the leading cause of death in the world [57]. Atherosclerosis is a pathological process that involves plaque build-up in the walls of the arteries [58]. LPC levels in the circulation are associated with the development of atherosclerotic plaques and endothelial cell dysfunction [58,59,60,61]. Some LPC species can be diagnostic markers for myocardial infarction [62]. LPC content is increased in circulating modified low-density lipoprotein (LDL) [63], enzymatically degraded LDL [64], and oxidized LDL [64,65]. In addition, LPC promotes fatty acid-induced insulin resistance [66] and inhibits endothelial progenitor cell revitalization [67]. LPC and LDL levels are increased in the plasma of patients with familial hyperlipidemia and diabetes [65,68,69] (Table 2), and treatment with simvastatin reduces Lp-PLA2 and LPC content [68]. Interestingly, several recent lipidomic profiling studies showed a negative correlation between LDL levels and the occurrence of cardiovascular diseases [51,52,53]. In addition, diabetes is an important risk factor for cardiovascular diseases; however, conflicting results have been reported on the correlation of LPC and diseases [4,70,71,72,73].

2.2. Lysophosphatidylcholine and Brain Diseases
Oligodendrocytes are myelin-producing cells that provide metabolic support for neurons and prevent neurodegeneration [78]. Myelination defects are seen in many brain diseases such as multiple sclerosis, stroke, schizophrenia, and Alzheimer’s disease [47,79]. LPC mediates pericyte loss, vascular barrier disruption, demyelination, and motor function defects [45,46,47]. In addition, LPC enhances the neurotoxicity of amyloid β1–42 peptide oligomer formation and neurotoxic protein aggregation, indicating that inhibiting LPC generation may be important in treating neurodegenerative diseases [80,81]. In one study, LPC levels were significantly increased in patients with repetitive mild traumatic brain injury [82]. However, other studies have shown that plasma levels of LPC were decreased in patients with Alzheimer’s disease [54,55] and that the LPC-to-PC ratio was also decreased either in plasma or in cerebrospinal fluid from patients with Alzheimer’s disease [56,77].

2.3. Brief Summary of Lysophosphatidylcholine in Human Disease
Through Notch1 and/or ERK1/2 signaling, LPC induces monocyte chemoattractant protein-1 and inflammatory cytokine expression and damages endothelial cells [18,19,50]. In addition, LPC activates monocytes and polarizes macrophage activation toward the M1 phenotype [30,34,41,44], leading to the development of atherosclerosis and cardiovascular diseases. In the brain, LPC promotes oligodendrocyte demyelination and pericyte loss, and impairs barrier function of the endothelium [45,46,47,48], leading to neurodegenerative diseases. LPC levels are determined by different mechanisms, including LPC production, clearance, and degradation. Overproduction of LPC and/or increasing LPC levels in LDL particles, or in tissue, are positively correlated with disease development.

3. Mechanisms for Increased Circulating Lysophosphatidylcholine Levels
3.1. Increased Degradation of Phosphatidylcholine by Lipoprotein-Associated Phospholipase A2
PC synthesized in the liver is the most abundant lipid component (up to 70% mole ratio) of plasma very low density lipoprotein (VLDL) and also makes up close to 40% of nascent high-density lipoprotein (HDL) [83,84]. In the liver, PC is involved in VLDL secretion [85,86,87] and HDL metabolism [88,89]. After being secreted into the blood stream, PC on lipoprotein particles is degraded at the Sn-2 position of an oxidized fatty acid by the hydrolysis of Lp-PLA2 (Figure 1). LPC is then produced under a variety of physiological and pathological conditions. In atherosclerotic plaque, macrophages produce Lp-PLA2, which is then secreted into the circulatory system [90]. ApoCIII, OxLDL, serum amyloid A, and leukocyte activation are associated with the regulation and activation of Lp-PLA2 expression [91,92,93]. In contrast, nitro-oleic acid downregulates Lp-PLA2 expression [94]. Extensive clinical evidence indicates that the quantity and activity of Lp-PLA2 are positively correlated with cardiovascular events [27,95,96,97]. Quantifying plasma Lp-PLA2 is useful for identifying plaque instability, acute coronary syndrome, and other cardiovascular diseases [98,99,100]. Moreover, Lp-PLA2 is a predictor for incident ischemic stroke severity, early neurological deterioration in patients with acute ischemic stroke, and delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage [101,102,103]. However, inhibiting Lp-PLA2 by darapladib, a synthetic specific small molecular weight inhibitor of platelet-activating factor-acetylhydrolase (PAF-AH), did not yield promising results in clinical trials [104,105]. Although Lp-PLA2 has the anti-inflammatory function of degrading PAF [106,107] and thus reduces platelet activation, it also has the proinflammatory properties of increasing LPC and oxidized non-esterified fatty acids levels, which may be associated with the development of atherosclerosis [16,108]. Another potential future strategy for inhibiting Lp-PLA2 may involve the use of combined RNA interference (RNAi), which ameliorated atherosclerosis in apolipoprotein E-deficient mice [109].

3.2. Increased Degradation of Phosphatidylcholine by Lecithin-Cholesterol Acyltransferase
LCAT is secreted from the liver and catalyzes the transfer of the fatty acids at position sn-2 of PC to free cholesterol in plasma, which results in the formation of cholesterol esters and LPC on the surface of HDL and LDL [110,111] (Figure 1). In the brain, LCAT is synthesized by primary astrocytes and is activated by apolipoprotein E (apoE) secreted by glial cells [112]. The effect of LCAT on human atherogenesis is controversial [113,114]. Genetic deficiency of LCAT leads to the accumulation of nascent pre-β HDL in the circulation and development of atherosclerosis and acute coronary syndrome [114,115,116,117,118,119,120,121]. In golden Syrian hamsters, the loss of LCAT activity led to dyslipidemia and atherosclerosis [122]. In addition, proteomic studies in LCAT deficiency showed that plasma levels of HDL-C, apoAI, and apoAI were decreased, leading to corneal opacity, hemolytic anemia, and renal disease [123]. In contrast, overexpression of LCAT is associated with the formation of large apoE-rich HDL and liver cholesterol [124,125]. Higher LCAT activity is correlated with insulin resistance and nonalcoholic fatty liver disease [126]. The LDL-particle size can be reduced and positively associated with atherosclerotic cardiovascular disease [127]. However, in some cases, increased LCAT levels are associated with a reduced coronary atheroma burden [128]. Interestingly, LCAT levels did not differ in LCAT-transgenic mice and wild-type mice [129]. The detailed mechanisms are unclear.

3.3. Hypoxia Condition Regulates Glycolysis and Lysophosphatidylcholine Overproduction
Hypoxia induces a reprogramming of cell respiration and carbohydrate metabolism [130]. Under hypoxic conditions, hypoxia-inducible factor (HIF)-1 alters the expression profile of glycolytic molecules and regulates glycolysis [131]. In addition, HIF-1 in the liver activates sterol regulatory element binding protein-1 and stearoyl-coenzyme A desaturase, which are key regulatory genes in the biosynthesis of triglycerides and phospholipids [132]. Trzepizur et al. examined serum lipid levels in 2018 fasting patients and found that nocturnal intermittent hypoxia and obstructive sleep apnea severity were associated with higher triglyceride and lower HDL-C levels [133]. In cardiovascular diseases, intermittent hypoxia leads to cardiomyocyte apoptosis and inflammation through protein O-GlcNAc glycosylation and phosphorylation of the p38 mitogen-activated protein kinase [134]. Some lipidomic studies showed that hypoxia stimulation caused a prominent increase in the amount of LPC [135]. In addition, findings from a lipid consumption study also suggested that LPC provides a more accessible nutrient source for cell proliferation under hypoxia [136]. In AbPPSwe/PSIdE9 mice, chronic intermittent hypoxia triggered earlier learning memory impairment. In a symptomatic N5 TgCRND8 mouse model of Alzheimer’s disease, cytosolic phospholipase A2α activity progressively increased; overall LPC levels progressively rose. The authors concluded that disruptions in Lands cycle metabolism were linked to the onset of symptoms and a progressive behavioral decline in mice with pre-existing Aβ pathology [137]. However, the detailed effects of hypoxia on lipid metabolism in humans are not well understood.

4. Transportation of Lysophosphatidylcholine in the Circulatory System
Plasma LPC is rapidly cleared from circulation by transporters such as albumin and alpha-1 acid glycoprotein (AGP) to the liver for the synthesis of PC [138], or it accumulates in the brain for the production of acetylcholine [139] (Figure 1). Although overproduction of LPC can occur through different mechanisms as mentioned above, it can also accumulate in oxidized LDL and is associated with vascular inflammation [140,141].

4.1. Albumin
About 80% of LPC is bound to albumin [142,143]. Hypoalbuminemia due to proteinuria results in a decrease in albumin-LPC binding and an increase in LPC levels in VLDL, intermediate-density lipoprotein, and LDL [144]. Increased levels of LPC in LDL of hyperlipidemic patients were associated with nephrotic syndrome [145]. In another study, albumin was found to be protective in LPC-induced attenuation of vasodilation [146]. Moreover, albumin counteracted LPC-induced renal vasoconstriction [147], suggesting that albumin is a potent buffer for the effects of LPC.

4.2. Alpha-1 Acid Glycoprotein
The concentration of AGP in the plasma increases under inflammatory conditions. Similar to the function of antitrypsin, AGP exerts anti-inflammatory effects by inhibiting platelet aggregation, preventing superoxide production, and attenuating TNF-α effects on cells [148]. In addition, AGP maintains capillary permeability and prevents apoptosis in ischemia/reperfusion injury. With a higher binding affinity to LPC, AGP complements albumin as a lysophospholipid-scavenging protein, especially in inflammatory conditions in which albumin-sequestering capacity is weakened [138].

4.3. Transmembrane Transporter Protein
P4-ATPases are lipid flippases expressed on the eukaryotic plasma membrane. They function in translocating phospholipids from the exoplasm to the cytosolic area against a concentration gradient via ATP hydrolysis [149,150]. In a reverse process, LPC can be exported by the action of ATP-binding cassette transporter A7 (ABCA7) in the presence of apolipoprotein AI (apoAI) and apoE [151,152]. Mutations of ABCA7 are associated with neurodegenerative diseases [153]. The possible mechanism may involve a scenario in which excess LPC synergistically enhances Aβ1-42-induced neuronal apoptosis [154,155].

4.4. Oxidized Low Density Liopoprotein
Human lipoproteins, including VLDL, LDL, and HDL, contain LPC. However, the levels of LPC in these lipoproteins are debated [65,156,157]. Using electrospray ionization and matrix-assisted laser desorption/ionization mass spectrometry, Stübiger et al. reported that LPC concentration was increased in patients with familial hypercholesterolemia or familial combined hyperlipidemia [65]. Specifically, the amount of bioactive lipid LPC is increased up to 5 times in circulating modified LDL or OxLDL [63,65,158]. Because of the atherogenicity of LPC, OxLDL modulates dendritic cell phenotypic and functional maturation [159,160], triggers adipocyte activation and plasminogen activator inhibitor-1 secretion [40], leads to endothelial damage by inhibiting Ca2+ influx and NO synthesis [161], and promotes human artery smooth muscle cells proliferation and migration [162]. These pathophysiological implications make LPC a promising target for biomarker and treatment of atherosclerosis and cardiovascular disorders [162,163].

5. Lysophosphatidylcholine Turnover
5.1. Lysophosphatidylcholine Clearance by Acyltransferases in Various Tissues
Under normal physiological conditions, LPC is cleared by enzymes such as acyl-CoA:LPCAT [164], located in the endoplasmic reticulum within alveolar type II cells in the lung [10], in lipid droplets [12], in red blood cells [164], in hepatocytes [11,165], and in other cell types (Figure 1). At least four LPCAT subtypes have been identified [166]. Among them, overexpression of the LPCAT1 gene may contribute to the progression and metastasis of human cancers, such as hepatocellular carcinoma [167], oral squamous cell carcinoma [168], breast cancer [169], prostate cancer [170], and colorectal cancer [171]. LPCAT2 supports lipid droplet production, and its overexpression inhibits the function of chemotherapeutic agents for colorectal cancer [172]. Expression of the LPCAT2 gene is upregulated in breast and cervical cancers [173]. LPCAT3 is regulated by peroxisome proliferator-activated receptor δ. Transient liver-specific knockdown of LPCAT3 in mice attenuated the fatty acid metabolic pathway [11,165]. In another study, LPCAT3 knockdown resulted in LPC accumulation in the liver but promoted VLDL secretion and microsomal triglyceride transfer protein expression [174]. In addition, LPCAT3 deficiency reduced lipid adsorption in small intestine [175]. LPCAT4 is also called acyl-CoA:lysophosphatidylethanolamine acyltransferase 2 and is primarily expressed in the brain [176]. In colorectal cancer, LPCAT4 levels are elevated [177]. Tumor necrosis factor-α and transforming growth factor-β1 induced the expression of LPCAT2 and LPCAT4 [178,179].

5.2. Degradation of Lysophosphatidylcholine by Lysophospholipases in the Circulation
The hydrolysis of LPC can be catalyzed by lysophospholipases A1, C, or D, according to the cleavage site (Figure 2). In neutrophils in humans, phospholipase B-like 1 exhibits weak lysophospholipase A1 activity [180]. Autotaxin has lysophospholipase D activity; the product resulting from the action of autotaxin—lysophosphatidic acid (LPA)—is associated with cancer and other inflammatory diseases. To date, no enzyme has been documented to exhibit lysophospholipase C activity.

5.2.1. Enzymes with Lysophospholipases A1 Activity
Galectin-10: Also known as Charcot-Leyden crystal protein, galectin-10 was first described by Charcot and Robin more than 150 years ago. Galectin-10 is associated with eosinophil- or basophil-mediated inflammation involved with allergy responses [181,182]. Initially, galectin-10 was falsely considered to have weak lipase activity [183] but was later shown to bind a pancreatic-like lysophospholipase in human eosinophils and to inhibit lipolytic activity [184,185]. Highly expressed in eosinophils, galectin-10 is associated with the formation of Charcot-Leyden crystals in lymphocytes; however, the function of the crystals is not fully understood [186].

Phospholipase B-like 1: The membrane-bound protein from neutrophils exhibited weak phospholipase activity for various phospholipids, including LPC [180]; the investigators suggested that phospholipase B-like 1 may play a role in the response against microorganisms and inflammation. Phospholipase B-like 1 is highly expressed on leukocytes in patients with ischemic stroke [187,188], but the detailed mechanisms are not clear.

Lysophospholipase I (encoded by the LYPLA1 gene) was first cloned from human brain tissue [189,190]. Similar to lysophospholipase I, the paralog lysophospholipase II (encoded by the LYPLA2 gene) is a cytosolic enzyme that is transported through the cell membrane by palmitoylation [191]. Interference by using small molecules such as palmostatin B inhibits Ras localization and signaling through lysophospholipase acylation [192]. Both lysophospolipase I and II are now classified as EC 3.1.2.22 (UniProt, release 2019_01) and have been renamed acyl-protein thioesterase 1 and 2 (APT-1/APT-2) because they have depalmitoylating activity but low lysophospholipase activity [192,193,194]. Although the alternative names are APT-1/APT-2 and lysophospholipase I/II (LysoPLA I/LysoPLA II), the major functions of these enzymes differ from those of lysophospholipase A1 (lysoPLA1), which is classified as EC 3.1.1.5. Instead, the depalmitoylating activity of APT-1/APT-2 is associated with membrane protein localization and signaling such as Ras [192].

5.2.2. Enzymes with Lysophospholipases D Activity
Autotaxin: Autotaxin, also called ecto-nucleotide pyrophosphatase/phosphodiesterase-2, is a secreted exo-enzyme that produces most of the extracellular lipid mediator, LPA [195,196]. Autotaxin hydrolyzes phosphodiester bonds of nucleoside triphosphates, lysophospholipids, and cholinephosphate esters [197]. The unique lysophospholipase D activity of autotaxin is determined by a characteristic bimetallic active site and a deep lipid-binding pocket [198]. Originally isolated from human melanoma A2058 cells and defined as an “autocrine motility factor” [199], autotaxin plays a major role in the development of the embryonic vasculature and neural tissue [200,201,202] and in wound healing [203]. However, autotaxin also stimulates tumor cell motility and contributes to the progression of breast cancer [204]. In addition, autotaxin promotes bone cancer metastasis [205], increases the proliferation of thyroid cancer cells [206], and provides cells with resistance to chemotherapy [207]. Moreover, patients with liver fibrosis or hepatocellular carcinoma have increased levels of autotaxin [208,209].

LPA signaling and function: The LPA concentration in plasma ranges between 100 to 164 nM, which is about 1000 times less than that of LPC [210,211,212]. Extracellular LPA is generated via several mechanisms, including the action of phospholipases (group IIA secretory phospholipase A2; sPLA2-IIA and phosphatidylserine-specific phospholipase A1; and PS-PLA1) and removal of the choline moiety from LPC by autotaxin [213,214]. Platelets are a major source of LPA because of the presence of autotaxin in their α-granules, and secreted autotaxin is responsible for the basal concentration of LPA in blood [215]. There are six LPA-associated G protein-coupled receptors (GPCRs), LPA1–6 or LPAR1–6, involved in autotaxin–LPA axis signaling [216,217]. LPA induces a variety of responses such as cell proliferation and migration and cytokine production via GPCR signaling and the effects on ion channels under normal and pathological conditions [218]. LPA plays an important physiological role in the functioning of the immune system. It promotes the homing of lymphocytes to secondary lymphoid tissue through high endothelial venules [219] and stimulates the polarization and transendothelial migration of naïve T cells [220].

LPA and diseases: LPA signaling is associated with metabolic and inflammatory disorders including obesity, insulin resistance, atherosclerosis, and myocardial infarction [221,222,223]. Either by autotaxin overexpression or by supplemented LPA intake, LPA impairs paraoxonase/arylesterase activity and inhibits scavenger receptor BI expression but promotes matrix metalloproteinase-9 activation in THP-1 cells, which results in foam cell formation and atherosclerosis [222,224,225]. Treatment targeting LPA receptors and the downstream signaling pathway attenuates atherosclerosis progression in LDL-receptor deficient mice [226]. In addition, the LPA inactivator, phospholipid phosphatase 3 (PLPP3), is repressed in advanced stages of human atherosclerosis [227]. In mice, inactivation of PLPP3 led to myocardial dysfunction and heart failure [228]. These data indicate that LPA signaling may be an important therapeutic target. LPA stimulates angiogenesis, cancer cell growth, and metastasis [229,230]. High levels of autotaxin/LPA correlate with breast cancer, type I endometrial cancer, and formation of other tumors [231,232,233]. LPA impairs autophagy and regulates tumor progression in various cancer cells [234,235,236,237]. LPA and autotaxin are also highly expressed in the central nervous system, promoting lymphocyte circulation and maturation [219]. Dysregulation of LPA contributes to the pathogenesis of Alzheimer’s disease and mild cognitive impairment in patients with type 2 diabetes [238,239,240].

6. Conclusions
LPC, via G protein-coupled receptor signaling, has harmful effects on various cells that include enhancing inflammatory responses, disrupting mitochondrial integrity, and inducing apoptosis. However, the optimal level of LPC in the plasma has not been established, and the mechanisms underlying LPC’s harmful effects are not well understood. Levels of LPC in LDL positively correlate with disease development. An increase in LPC levels is determined primarily by enzyme activity—Lp-PLA2 for LPC production. LPCAT contributes to reducing LPC levels; however, the overexpression of LPCAT is associated with cancer. Direct degradation of LPC by autotaxin with lysophospholipase D activity produces LPA, which is another mediator that is highly associated with cancers. Enzymes with lysophospholipaseA1 activity can degrade LPC into harmless materials, but no enzyme with strong lysophospholipase A1 activity has been identified. Targeting LPC may be an important therapeutic option for treating cardiovascular and neurodegenerative diseases. The use of RNAi to inhibit Lp-PLA2 or enzyme lysophospholipase A1 activity may potentially be an effective future strategy. In summary, gaining a better understanding of the enzymes and non-enzyme proteins involved in LPC metabolism and how their levels correlate with disease conditions may be useful in identifying novel therapeutic targets for LPC-associated diseases.

Acknowledgments
In addition, we thank for Günter Schwarz from Cologne University, and Shau-Ku Huang from Johns Hopkins University School of Medicine, Baltimore, MD, USA for revising and final editing of this paper. The authors thank Rebecca Bartow, PhD, of the Texas Heart Institute in Houston, Texas, USA for editorial assistance.

Author Contributions
S.-H.L., F.P. wrote and reviewed the manuscripts; M.-L.C. organized and constructed tables and figures; G.K.M. and C.-H.C. reviewed the final draft of the manuscript and critically revised the manuscript for important intellectual content; L.-Y.K. conceptualized the manuscript.

Funding
This work was supported in part by grants from the Vascular and Medicinal Research Fund, Texas Heart Institute (#765-64050) to C.-H.C.; the Kaohsiung Medical University grant (KMU-TP105D14, KMU-DK107012) to L.-Y.K., (KMUH106-6R64, KMUH107-7R66) to C.-H.C.; and Taiwan Ministry of Science and Technology (MOST 105-2320-B-037-004-MY3, MOST 107-2314-B-037-114-MY3, MOST107-2911-I-037-505) to L.-Y.K., (MOST106-2321-B-037-003, 107-2321-B-037-002, 106-2314-B-037-069-) to C.-H.C. respectively.

Conflicts of Interest
The authors declare no conflict of interest.

Abbreviations
AGP	Alpha-1 acid glycoprotein	
HDL	High-density lipoprotein	
LCAT	Lecithin-cholesterol acyltransferase	
LDL	Low-density lipoprotein	
LPA	Lysophosphatidic acid	
LPC	Lysophosphatidylcholine	
LPCAT	Lysophosphatidylcholine acyltransferase	
VLDL	Very low density lipoprotein	
Figure 1 Phosphatidylcholines (PCs) are synthesized in the liver and secreted as components of very low density lipoprotein (VLDL). PCs are degraded via hydrolysis by Lp-PLA2 or conversion by LCAT. The metabolites, LPCs, can be transported back to the liver by albumin or AGP and then cleared by LPCAT in the presence of acyl-CoA. The actions of these two distinct enzymes form a cycle of PC degradation and regeneration called the Lands cycle. Excess circulating LPCs may be released or carried on OxLDL to exert harmful effects on various cells though LOX-1, lipid flippase, and G protein-coupled receptor signaling. LPCs can also undergo further hydrolysis by lysoPLD such as autotaxin to become LPA, another important inflammatory mediator. Green arrows indicate occurrence under normal physiologic conditions. Red arrows indicate the promotion of inflammation.

Figure 2 The hydrolysis of LPC is catalyzed by lysophospholipases A1, C, or D, according to the cleavage site.

ijms-20-01149-t001_Table 1Table 1 Summary of reported effects of LPC on various cell types.

Cell Type	Effects of LPC	References	
Endothelial cells	Induces MCP-1 expression	[17,49]	
Induces inflammatory damage through Notch1 signaling, the overexpression of Notch1, Hes1, and MCP-1	[50]	
Induces MCP-1, IL-8 and RANTES expression through the phosphorylation of ERK1/2, AKT and p38 MAP kinase	[18]	
Induces cytotoxicity/apoptosis and IL-8 production	[19]	
Increases oxidative stress	[21,22]	
Inhibits endothelial cell migration and proliferation	[23,24]	
Impairs endothelium-dependent arterial relaxation	[20]	
Adipocytes	Increases IL-1β, IL-6, TNF-α release from adipocytes	[39,40]	
Hepatocytes	Disrupts mitochondrial integrity and enhances cytochrome C release	[13]	
Immune cells	Induces IFN-γ and TNF-α secretion, immune activation	[16]	
Activates macrophages	[30,34,41]	
Polarizes macrophage activation toward M1 phenotype	[44]	
Activates B cells	[16]	
Induces regulatory T-cell (nTregs) differentiation through Foxp3 expression and TGF-β1 production	[42]	
Neuron cells	Impaired the barrier function of the endothelium in the brain microvasculature and induced inflammation	[46]	
Mediates pericyte loss	[47]	
Induces oligodendrocyte demyelination	[45,48]	
ERK, extracellular signal-regulated kinase; IFN, interferon; IL, interleukin; LPC, lysophosphatidylcholine; MAP, mitogen-activated protein; MCP-1, monocyte chemoattractant protein-1; TGF, transforming growth factor; TNF, tumor necrosis factor.

ijms-20-01149-t002_Table 2Table 2 LPC levels in circulation, LDL, or tissue.

Disease	LPC Levels in Plasma or Serum	LPC Levels in LDL Particle	LPC Levels in Tissues	
Familial combined hyperlipidemia	1.4× increased [65]	About 1.5× increased LPC concentration in oxidized LDL [65]	N/A	
Cardiovascular diseases	LPCs showed an inverse relationship [51,52,53]	About 2× increased LPC concentration in circulating modified LDL [63]	N/A	
Diabetes	1.5× increased LPC [4]. Positively associated with blood pressure, carotid artery intima media thickness [70]. Negatively correlated with type 2 diabetes [71,72,73]	1.2–2.8× increased positively correlative with disease progression [49,68]	2-arachidonoyl-lysophosphatidyl-choline increased in atheroma plaques [74]	
Myocardial infarction	LPCs 17:0 and LPC 18:2 were selected as biomarkers [62]	N/A	N/A	
Stroke	N/A	N/A	LPC 22:6 increased in hippocampus [75]; LPC (16:0) increased in ischemic cerebral regions [76]	
Alzheimer’s disease	Plasma level of LPC decreased [54,55]. LPC:PC ratio decreased either in plasma or cerebrospinal fluid [56,77]	N/A	N/A	
LDL, low-density lipoprotein; LPC, lysophosphatidylcholine; PC, phosphatidylcholine.
==== Refs
References
1. Ridgway N.  McLeod R.   Biochemistry of Lipids, Lipoproteins and Membranes 6th ed. Elsevier Amsterdam, The Netherlands 2016 
2. Gauster M.  Rechberger G.  Sovic A.  Horl G.  Steyrer E.  Sattler W.  Frank S.   Endothelial lipase releases saturated and unsaturated fatty acids of high density lipoprotein phosphatidylcholine J. Lipid Res. 2005 46 1517 1525 10.1194/jlr.M500054-JLR200 15834125 
3. Dullaart R.P.  Gansevoort R.T.  Dikkeschei B.D.  de Zeeuw D.  de Jong P.E.  van Tol A.   Role of elevated lecithin: Cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients Kidney Int 1993 44 91 97 10.1038/ki.1993.217 8355471 
4. Rabini R.A.  Galassi R.  Fumelli P.  Dousset N.  Solera M.L.  Valdiguie P.  Curatola G.  Ferretti G.  Taus M.  Mazzanti L.   Reduced Na(+)-K(+)-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients Diabetes 1994 43 915 919 10.2337/diab.43.7.915 8013757 
5. Okita M.  Gaudette D.C.  Mills G.B.  Holub B.J.   Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients Int. J. Cancer 1997 71 31 34 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4 9096662 
6. Sasagawa T.  Suzuki K.  Shiota T.  Kondo T.  Okita M.   The significance of plasma lysophospholipids in patients with renal failure on hemodialysis J. Nutr. Sci. Vitaminol. 1998 44 809 818 10.3177/jnsv.44.809 10197312 
7. Zeisel S.H.   A brief history of choline Ann. Nutr. Metab. 2012 61 254 258 10.1159/000343120 23183298 
8. Watson H.   Biological membranes Essays Biochem. 2015 59 43 69 10.1042/bse0590043 26504250 
9. Wang L.  Shen W.  Kazachkov M.  Chen G.  Chen Q.  Carlsson A.S.  Stymne S.  Weselake R.J.  Zou J.   Metabolic interactions between the Lands cycle and the Kennedy pathway of glycerolipid synthesis in Arabidopsis developing seeds Plant Cell 2012 24 4652 4669 10.1105/tpc.112.104604 23150634 
10. Chen X.  Hyatt B.A.  Mucenski M.L.  Mason R.J.  Shannon J.M.   Identification and characterization of a lysophosphatidylcholine acyltransferase in alveolar type II cells Proc. Natl. Acad. Sci. USA 2006 103 11724 11729 10.1073/pnas.0604946103 16864775 
11. Zhao Y.  Chen Y.Q.  Bonacci T.M.  Bredt D.S.  Li S.  Bensch W.R.  Moller D.E.  Kowala M.  Konrad R.J.  Cao G.   Identification and characterization of a major liver lysophosphatidylcholine acyltransferase J. Biol. Chem. 2008 283 8258 8265 10.1074/jbc.M710422200 18195019 
12. Moessinger C.  Kuerschner L.  Spandl J.  Shevchenko A.  Thiele C.   Human lysophosphatidylcholine acyltransferases 1 and 2 are located in lipid droplets where they catalyze the formation of phosphatidylcholine J. Biol. Chem. 2011 286 21330 21339 10.1074/jbc.M110.202424 21498505 
13. Hollie N.I.  Cash J.G.  Matlib M.A.  Wortman M.  Basford J.E.  Abplanalp W.  Hui D.Y.   Micromolar changes in lysophosphatidylcholine concentration cause minor effects on mitochondrial permeability but major alterations in function Biochim. Biophys. Acta 2014 1841 888 895 10.1016/j.bbalip.2013.11.013 24315825 
14. Li X.  Wang L.  Fang P.  Sun Y.  Jiang X.  Wang H.  Yang X.F.   Lysophospholipids induce innate immune transdifferentiation of endothelial cells, resulting in prolonged endothelial activation J. Biol. Chem. 2018 10.1074/jbc.RA118.002752 29769317 
15. Wong J.T.  Tran K.  Pierce G.N.  Chan A.C.  Karmin O.  Choy P.C.   Lysophosphatidylcholine stimulates the release of arachidonic acid in human endothelial cells J. Biol. Chem. 1998 273 6830 6836 10.1074/jbc.273.12.6830 9506985 
16. Huang Y.H.  Schafer-Elinder L.  Wu R.  Claesson H.E.  Frostegard J.   Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism Clin. Exp. Immunol. 1999 116 326 331 10.1046/j.1365-2249.1999.00871.x 10337026 
17. Takahara N.  Kashiwagi A.  Maegawa H.  Shigeta Y.   Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells Metabolism 1996 45 559 564 10.1016/S0026-0495(96)90024-4 8622597 
18. Murugesan G.  Sandhya Rani M.R.  Gerber C.E.  Mukhopadhyay C.  Ransohoff R.M.  Chisolm G.M.  Kottke-Marchant K.   Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines J. Mol. Cell. Cardiol. 2003 35 1375 1384 10.1016/j.yjmcc.2003.08.004 14596794 
19. Chang M.C.  Lee J.J.  Chen Y.J.  Lin S.I.  Lin L.D.  Jein-Wen Liou E.  Huang W.L.  Chan C.P.  Huang C.C.  Jeng J.H.   Lysophosphatidylcholine induces cytotoxicity/apoptosis and IL-8 production of human endothelial cells: Related mechanisms Oncotarget 2017 8 106177 106189 10.18632/oncotarget.22425 29290940 
20. Kugiyama K.  Kerns S.A.  Morrisett J.D.  Roberts R.  Henry P.D.   Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins Nature 1990 344 160 162 10.1038/344160a0 2106627 
21. Kim E.A.  Kim J.A.  Park M.H.  Jung S.C.  Suh S.H.  Pang M.G.  Kim Y.J.   Lysophosphatidylcholine induces endothelial cell injury by nitric oxide production through oxidative stress J. Matern. Fetal Neonatal Med. 2009 22 325 331 10.1080/14767050802556075 19089771 
22. Li B.  Tian S.  Liu X.  He C.  Ding Z.  Shan Y.   Sulforaphane protected the injury of human vascular endothelial cell induced by LPC through up-regulating endogenous antioxidants and phase II enzymes Food Funct. 2015 6 1984 1991 10.1039/C5FO00438A 26008201 
23. Chaudhuri P.  Colles S.M.  Damron D.S.  Graham L.M.   Lysophosphatidylcholine inhibits endothelial cell migration by increasing intracellular calcium and activating calpain Arterioscler. Thromb. Vasc. Biol. 2003 23 218 223 10.1161/01.ATV.0000052673.77316.01 12588762 
24. Rikitake Y.  Kawashima S.  Yamashita T.  Ueyama T.  Ishido S.  Hotta H.  Hirata K.  Yokoyama M.   Lysophosphatidylcholine inhibits endothelial cell migration and proliferation via inhibition of the extracellular signal-regulated kinase pathway Arterioscler. Thromb. Vasc. Biol. 2000 20 1006 1012 10.1161/01.ATV.20.4.1006 10764665 
25. Schmitz G.  Ruebsaamen K.   Metabolism and atherogenic disease association of lysophosphatidylcholine Atherosclerosis 2010 208 10 18 10.1016/j.atherosclerosis.2009.05.029 19570538 
26. Zahednasab H.  Balood M.  Harirchian M.H.  Mesbah-Namin S.A.  Rahimian N.  Siroos B.   Increased autotaxin activity in multiple sclerosis J. Neuroimmunol. 2014 273 120 123 10.1016/j.jneuroim.2014.06.006 24984830 
27. Lehto L.J.  Albors A.A.  Sierra A.  Tolppanen L.  Eberly L.E.  Mangia S.  Nurmi A.  Michaeli S.  Grohn O.   Lysophosphatidyl Choline Induced Demyelination in Rat Probed by Relaxation along a Fictitious Field in High Rank Rotating Frame Front. Neurosci. 2017 11 433 10.3389/fnins.2017.00433 28824359 
28. Packard C.J.  O’Reilly D.S.  Caslake M.J.  McMahon A.D.  Ford I.  Cooney J.  Macphee C.H.  Suckling K.E.  Krishna M.  Wilkinson F.E.    Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group N. Engl. J. Med. 2000 343 1148 1155 10.1056/NEJM200010193431603 11036120 
29. Thompson A.  Gao P.  Orfei L.  Watson S.  Di E.A.  Kaptoge S.  Ballantyne C.  Cannon C.P.  Criqui M.  Cushman M.    Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies Lancet 2010 375 1536 1544 20435228 
30. Yang L.V.  Radu C.G.  Wang L.  Riedinger M.  Witte O.N.   Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A Blood 2005 105 1127 1134 10.1182/blood-2004-05-1916 15383458 
31. Radu C.G.  Yang L.V.  Riedinger M.  Au M.  Witte O.N.   T cell chemotaxis to lysophosphatidylcholine through the G2A receptor Proc. Natl. Acad. Sci. USA 2004 101 245 250 10.1073/pnas.2536801100 14681556 
32. Tan M.  Hao F.  Xu X.  Chisolm G.M.  Cui M.Z.   Lysophosphatidylcholine activates a novel PKD2-mediated signaling pathway that controls monocyte migration Arterioscler. Thromb. Vasc. Biol. 2009 29 1376 1382 10.1161/ATVBAHA.109.191585 19520973 
33. Peter C.  Waibel M.  Radu C.G.  Yang L.V.  Witte O.N.  Schulze-Osthoff K.  Wesselborg S.  Lauber K.   Migration to apoptotic “find-me” signals is mediated via the phagocyte receptor G2A J. Biol. Chem. 2008 283 5296 5305 10.1074/jbc.M706586200 18089568 
34. Carneiro A.B.  Iaciura B.M.  Nohara L.L.  Lopes C.D.  Veas E.M.  Mariano V.S.  Bozza P.T.  Lopes U.G.  Atella G.C.  Almeida I.C.    Lysophosphatidylcholine triggers TLR2- and TLR4-mediated signaling pathways but counteracts LPS-induced NO synthesis in peritoneal macrophages by inhibiting NF-kappaB translocation and MAPK/ERK phosphorylation PLoS ONE 2013 8 e76233 10.1371/journal.pone.0076233 24312681 
35. Witte O.N.  Kabarowski J.H.  Xu Y.  Le L.Q.  Zhu K.   Retraction Science 2005 307 206 10.1126/science.307.5707.206b 15653487 
36. Marathe G.K.  Silva A.R.  de Castro Faria Neto H.C.  Tjoelker L.W.  Prescott S.M.  Zimmerman G.A.  McIntyre T.M.   Lysophosphatidylcholine and lyso-PAF display PAF-like activity derived from contaminating phospholipids J. Lipid Res. 2001 42 1430 1437 11518762 
37. Kume N.  Gimbrone M.A. Jr.   Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells J. Clin. Investig. 1994 93 907 911 10.1172/JCI117047 7509351 
38. Kume N.  Cybulsky M.I.  Gimbrone M.A. Jr.   Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells J. Clin. Investig. 1992 90 1138 1144 10.1172/JCI115932 1381720 
39. Sato A.  Kumagai T.  Ebina K.   A synthetic biotinylated peptide, BP21, inhibits the induction of mRNA expression of inflammatory substances by oxidized- and lyso-phosphatidylcholine Drug Dev. Res. 2014 75 246 256 10.1002/ddr.21178 24890951 
40. Kuniyasu A.  Tokunaga M.  Yamamoto T.  Inoue S.  Obama K.  Kawahara K.  Nakayama H.   Oxidized LDL and lysophosphatidylcholine stimulate plasminogen activator inhibitor-1 expression through reactive oxygen species generation and ERK1/2 activation in 3T3-L1 adipocytes Biochim. Biophys. Acta 2011 1811 153 162 10.1016/j.bbalip.2010.11.011 21146630 
41. Yamamoto N.  Homma S.  Millman I.   Identification of the serum factor required for in vitro activation of macrophages. Role of vitamin D3-binding protein (group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages J. Immunol. 1991 147 273 280 2051023 
42. Hasegawa H.  Lei J.  Matsumoto T.  Onishi S.  Suemori K.  Yasukawa M.   Lysophosphatidylcholine enhances the suppressive function of human naturally occurring regulatory T cells through TGF-beta production Biochem. Biophys. Res. Commun. 2011 415 526 531 10.1016/j.bbrc.2011.10.119 22074829 
43. Shevach E.M.   Mechanisms of foxp3+ T regulatory cell-mediated suppression Immunity 2009 30 636 645 10.1016/j.immuni.2009.04.010 19464986 
44. Qin X.  Qiu C.  Zhao L.   Lysophosphatidylcholine perpetuates macrophage polarization toward classically activated phenotype in inflammation Cell. Immunol. 2014 289 185 190 10.1016/j.cellimm.2014.04.010 24841857 
45. Ou Z.  Sun Y.  Lin L.  You N.  Liu X.  Li H.  Ma Y.  Cao L.  Han Y.  Liu M.    Olig2-Targeted G-Protein-Coupled Receptor Gpr17 Regulates Oligodendrocyte Survival in Response to Lysolecithin-Induced Demyelination J. Neurosci. 2016 36 10560 10573 10.1523/JNEUROSCI.0898-16.2016 27733608 
46. Qiao J.  Huang F.  Naikawadi R.P.  Kim K.S.  Said T.  Lum H.   Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4 Am. J. Physiol. Lung Cell. Mol. Physiol. 2006 291 L91 L101 10.1152/ajplung.00508.2005 16461426 
47. Muramatsu R.  Kuroda M.  Matoba K.  Lin H.  Takahashi C.  Koyama Y.  Yamashita T.   Prostacyclin prevents pericyte loss and demyelination induced by lysophosphatidylcholine in the central nervous system J. Biol. Chem. 2015 290 11515 11525 10.1074/jbc.M114.587253 25795781 
48. Plemel J.R.  Michaels N.J.  Weishaupt N.  Caprariello A.V.  Keough M.B.  Rogers J.A.  Yukseloglu A.  Lim J.  Patel V.V.  Rawji K.S.    Mechanisms of lysophosphatidylcholine-induced demyelination: A primary lipid disrupting myelinopathy Glia 2018 66 327 347 10.1002/glia.23245 29068088 
49. Takahara N.  Kashiwagi A.  Nishio Y.  Harada N.  Kojima H.  Maegawa H.  Hidaka H.  Kikkawa R.   Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells Diabetologia 1997 40 662 670 10.1007/s001250050731 9222645 
50. Zhao J.  Liang Y.  Song F.  Xu S.  Nian L.  Zhou X.  Wang S.   TSG attenuates LPC-induced endothelial cells inflammatory damage through notch signaling inhibition IUBMB Life 2016 68 37 50 10.1002/iub.1458 26662286 
51. Stegemann C.  Pechlaner R.  Willeit P.  Langley S.R.  Mangino M.  Mayr U.  Menni C.  Moayyeri A.  Santer P.  Rungger G.    Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study Circulation 2014 129 1821 1831 10.1161/CIRCULATIONAHA.113.002500 24622385 
52. Ganna A.  Salihovic S.  Sundstrom J.  Broeckling C.D.  Hedman A.K.  Magnusson P.K.  Pedersen N.L.  Larsson A.  Siegbahn A.  Zilmer M.    Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease PLoS Genet. 2014 10 e1004801 10.1371/journal.pgen.1004801 25502724 
53. Lee Y.K.  Lee D.H.  Kim J.K.  Park M.J.  Yan J.J.  Song D.K.  Vaziri N.D.  Noh J.W.   Lysophosphatidylcholine, oxidized low-density lipoprotein and cardiovascular disease in Korean hemodialysis patients: Analysis at 5 years of follow-up J. Korean Med. Sci. 2013 28 268 273 10.3346/jkms.2013.28.2.268 23400766 
54. Lin W.  Zhang J.  Liu Y.  Wu R.  Yang H.  Hu X.  Ling X.   Studies on diagnostic biomarkers and therapeutic mechanism of Alzheimer’s disease through metabolomics and hippocampal proteomics Eur. J. Pharm. Sci. 2017 105 119 126 10.1016/j.ejps.2017.05.003 28495476 
55. Mapstone M.  Cheema A.K.  Fiandaca M.S.  Zhong X.  Mhyre T.R.  MacArthur L.H.  Hall W.J.  Fisher S.G.  Peterson D.R.  Haley J.M.    Plasma phospholipids identify antecedent memory impairment in older adults Nat. Med. 2014 20 415 418 10.1038/nm.3466 24608097 
56. Klavins K.  Koal T.  Dallmann G.  Marksteiner J.  Kemmler G.  Humpel C.   The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer’s disease and mild cognitive impairment Alzheimers Dement. 2015 1 295 302 10.1016/j.dadm.2015.05.003 
57. Khan M.  Lamelas P.  Musa H.  Paty J.  McCready T.  Nieuwlaat R.  Ng E.  Lopez-Jaramillo P.  Lopez-Lopez J.  Yusoff K.    Development, Testing, and Implementation of a Training Curriculum for Nonphysician Health Workers to Reduce Cardiovascular Disease Glob. Heart 2018 13 93 100 10.1016/j.gheart.2017.11.002 29331282 
58. Li X.  Fang P.  Li Y.  Kuo Y.M.  Andrews A.J.  Nanayakkara G.  Johnson C.  Fu H.  Shan H.  Du F.    Mitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation Arterioscler. Thromb. Vasc. Biol. 2016 36 1090 1100 10.1161/ATVBAHA.115.306964 27127201 
59. Goncalves I.  Edsfeldt A.  Ko N.Y.  Grufman H.  Berg K.  Bjorkbacka H.  Nitulescu M.  Persson A.  Nilsson M.  Prehn C.    Evidence supporting a key role of Lp-PLA2-generated lysophosphatidylcholine in human atherosclerotic plaque inflammation Arterioscler. Thromb. Vasc. Biol. 2012 32 1505 1512 10.1161/ATVBAHA.112.249854 22499993 
60. Lavi S.  McConnell J.P.  Rihal C.S.  Prasad A.  Mathew V.  Lerman L.O.  Lerman A.   Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: Association with early coronary atherosclerosis and endothelial dysfunction in humans Circulation 2007 115 2715 2721 10.1161/CIRCULATIONAHA.106.671420 17502572 
61. Mannheim D.  Herrmann J.  Versari D.  Gossl M.  Meyer F.B.  McConnell J.P.  Lerman L.O.  Lerman A.   Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques Stroke 2008 39 1448 1455 10.1161/STROKEAHA.107.503193 18356547 
62. Ward-Caviness C.K.  Xu T.  Aspelund T.  Thorand B.  Montrone C.  Meisinger C.  Dunger-Kaltenbach I.  Zierer A.  Yu Z.  Helgadottir I.R.    Improvement of myocardial infarction risk prediction via inflammation-associated metabolite biomarkers Heart 2017 103 1278 1285 10.1136/heartjnl-2016-310789 28255100 
63. Zakiev E.R.  Sukhorukov V.N.  Melnichenko A.A.  Sobenin I.A.  Ivanova E.A.  Orekhov A.N.   Lipid composition of circulating multiple-modified low density lipoprotein Lipids Health Dis. 2016 15 134 10.1186/s12944-016-0308-2 27558696 
64. Orso E.  Matysik S.  Grandl M.  Liebisch G.  Schmitz G.   Human native, enzymatically modified and oxidized low density lipoproteins show different lipidomic pattern Biochim. Biophys. Acta 2015 1851 299 306 10.1016/j.bbalip.2015.01.001 25583048 
65. Stubiger G.  Aldover-Macasaet E.  Bicker W.  Sobal G.  Willfort-Ehringer A.  Pock K.  Bochkov V.  Widhalm K.  Belgacem O.   Targeted profiling of atherogenic phospholipids in human plasma and lipoproteins of hyperlipidemic patients using MALDI-QIT-TOF-MS/MS Atherosclerosis 2012 224 177 186 10.1016/j.atherosclerosis.2012.06.010 22795978 
66. Han M.S.  Lim Y.M.  Quan W.  Kim J.R.  Chung K.W.  Kang M.  Kim S.  Park S.Y.  Han J.S.  Park S.Y.    Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance J. Lipid Res. 2011 52 1234 1246 10.1194/jlr.M014787 21447485 
67. Hong S.H.  Jang H.H.  Lee S.R.  Lee K.H.  Woo J.S.  Kim J.B.  Kim W.-S.  Min B.I.  Cho K.H.  Kim K.S.    Impact of lysophosphatidylcholine on survival and function of UEA-1+acLDL+ endothelial progenitor cells in patients with coronary artery disease Heart Vessel. 2015 30 115 125 10.1007/s00380-014-0473-z 24510253 
68. Iwase M.  Sonoki K.  Sasaki N.  Ohdo S.  Higuchi S.  Hattori H.  Iida M.   Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: Relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment Atherosclerosis 2008 196 931 936 10.1016/j.atherosclerosis.2007.02.012 17350631 
69. Sonoki K.  Iwase M.  Sasaki N.  Ohdo S.  Higuchi S.  Matsuyama N.  Iida M.   Relations of lysophosphatidylcholine in low-density lipoprotein with serum lipoprotein-associated phospholipase A2, paraoxonase and homocysteine thiolactonase activities in patients with type 2 diabetes mellitus Diabetes Res. Clin. Pract. 2009 86 117 123 10.1016/j.diabres.2009.08.014 19748147 
70. Petersen K.S.  Keogh J.B.  Lister N.  Weir J.M.  Meikle P.J.  Clifton P.M.   Association between dairy intake, lipids and vascular structure and function in diabetes World J. Diabetes 2017 8 202 212 10.4239/wjd.v8.i5.202 28572881 
71. Wang-Sattler R.  Yu Z.  Herder C.  Messias A.C.  Floegel A.  He Y.  Heim K.  Campillos M.  Holzapfel C.  Thorand B.    Novel biomarkers for pre-diabetes identified by metabolomics Mol. Syst. Biol. 2012 8 615 10.1038/msb.2012.43 23010998 
72. Barber M.N.  Risis S.  Yang C.  Meikle P.J.  Staples M.  Febbraio M.A.  Bruce C.R.   Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes PLoS ONE 2012 7 e41456 10.1371/journal.pone.0041456 22848500 
73. Kopprasch S.  Dheban S.  Schuhmann K.  Xu A.  Schulte K.M.  Simeonovic C.J.  Schwarz P.E.  Bornstein S.R.  Shevchenko A.  Graessler J.   Detection of Independent Associations of Plasma Lipidomic Parameters with Insulin Sensitivity Indices Using Data Mining Methodology PLoS ONE 2016 11 e0164173 10.1371/journal.pone.0164173 27736893 
74. Menegaut L.  Masson D.  Abello N.  Denimal D.  Truntzer C.  Ducoroy P.  Lagrost L.  de Pais Barros J.P.  Athias A.  Petit J.M.    Specific enrichment of 2-arachidonoyl-lysophosphatidylcholine in carotid atheroma plaque from type 2 diabetic patients Atherosclerosis 2016 251 339 347 10.1016/j.atherosclerosis.2016.05.004 27189320 
75. Sabogal-Guaqueta A.M.  Posada-Duque R.  Cortes N.C.  Arias-Londono J.D.  Cardona-Gomez G.P.   Changes in the hippocampal and peripheral phospholipid profiles are associated with neurodegeneration hallmarks in a long-term global cerebral ischemia model: Attenuation by Linalool Neuropharmacology 2018 135 555 571 10.1016/j.neuropharm.2018.04.015 29680773 
76. Koizumi S.  Yamamoto S.  Hayasaka T.  Konishi Y.  Yamaguchi-Okada M.  Goto-Inoue N.  Sugiura Y.  Setou M.  Namba H.   Imaging mass spectrometry revealed the production of lyso-phosphatidylcholine in the injured ischemic rat brain Neuroscience 2010 168 219 225 10.1016/j.neuroscience.2010.03.056 20362643 
77. Mulder C.  Wahlund L.O.  Teerlink T.  Blomberg M.  Veerhuis R.  van Kamp G.J.  Scheltens P.  Scheffer P.G.   Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer’s disease J. Neural Transm. 2003 110 949 955 10.1007/s00702-003-0007-9 12898349 
78. Lee Y.  Morrison B.M.  Li Y.  Lengacher S.  Farah M.H.  Hoffman P.N.  Liu Y.  Tsingalia A.  Jin L.  Zhang P.W.    Oligodendroglia metabolically support axons and contribute to neurodegeneration Nature 2012 487 443 448 10.1038/nature11314 22801498 
79. Lu C.  Dong L.  Zhou H.  Li Q.  Huang G.  Bai S.J.  Liao L.   G-protein-coupled receptor Gpr17 regulates oligodendrocyte differentiation in response to lysolecithin-induced demyelination Sci. Rep. 2018 8 4502 10.1038/s41598-018-22452-0 29540737 
80. Sheikh A.M.  Michikawa M.  Kim S.U.  Nagai A.   Lysophosphatidylcholine increases the neurotoxicity of Alzheimer’s amyloid beta1-42 peptide: Role of oligomer formation Neuroscience 2015 292 159 169 10.1016/j.neuroscience.2015.02.034 25727637 
81. Kaya I.  Brinet D.  Michno W.  Baskurt M.  Zetterberg H.  Blenow K.  Hanrieder J.   Novel Trimodal MALDI Imaging Mass Spectrometry (IMS3) at 10 mum Reveals Spatial Lipid and Peptide Correlates Implicated in Abeta Plaque Pathology in Alzheimer’s Disease ACS Chem. Neurosci. 2017 8 2778 2790 10.1021/acschemneuro.7b00314 28925253 
82. Tzekov R.  Dawson C.  Orlando M.  Mouzon B.  Reed J.  Evans J.  Crynen G.  Mullan M.  Crawford F.   Sub-Chronic Neuropathological and Biochemical Changes in Mouse Visual System after Repetitive Mild Traumatic Brain Injury PLoS ONE 2016 11 e0153608 10.1371/journal.pone.0153608 27088355 
83. Agren J.J.  Kurvinen J.P.  Kuksis A.   Isolation of very low density lipoprotein phospholipids enriched in ethanolamine phospholipids from rats injected with Triton WR 1339 Biochim. Biophys. Acta 2005 1734 34 43 10.1016/j.bbalip.2005.02.001 15866481 
84. Skipski V.P.  Barclay M.  Barclay R.K.  Fetzer V.A.  Good J.J.  Archibald F.M.   Lipid composition of human serum lipoproteins Biochem. J. 1967 104 340 352 10.1042/bj1040340 6048776 
85. Yao Z.M.  Vance D.E.   The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes J. Biol. Chem. 1988 263 2998 3004 3343237 
86. Rinella M.E.  Elias M.S.  Smolak R.R.  Fu T.  Borensztajn J.  Green R.M.   Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet J. Lipid Res. 2008 49 1068 1076 10.1194/jlr.M800042-JLR200 18227531 
87. Fast D.G.  Vance D.E.   Nascent VLDL phospholipid composition is altered when phosphatidylcholine biosynthesis is inhibited: Evidence for a novel mechanism that regulates VLDL secretion Biochim. Biophys. Acta 1995 1258 159 168 10.1016/0005-2760(95)00116-T 7548179 
88. Jacobs R.L.  Devlin C.  Tabas I.  Vance D.E.   Targeted deletion of hepatic CTP:phosphocholine cytidylyltransferase alpha in mice decreases plasma high density and very low density lipoproteins J. Biol. Chem. 2004 279 47402 47410 10.1074/jbc.M404027200 15331603 
89. Noga A.A.  Vance D.E.   A gender-specific role for phosphatidylethanolamine N-methyltransferase-derived phosphatidylcholine in the regulation of plasma high density and very low density lipoproteins in mice J. Biol. Chem. 2003 278 21851 21859 10.1074/jbc.M301982200 12668679 
90. Hakkinen T.  Luoma J.S.  Hiltunen M.O.  Macphee C.H.  Milliner K.J.  Patel L.  Rice S.Q.  Tew D.G.  Karkola K.  Yla-Herttuala S.   Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions Arterioscler. Thromb. Vasc. Biol. 1999 19 2909 2917 10.1161/01.ATV.19.12.2909 10591668 
91. Han X.  Wang T.  Zhang J.  Liu X.  Li Z.  Wang G.  Song Q.  Pang D.  Ouyang H.  Tang X.   Apolipoprotein CIII regulates lipoprotein-associated phospholipase A2 expression via the MAPK and NFkappaB pathways Biol. Open 2015 4 661 665 10.1242/bio.201410900 25836672 
92. Shi Y.  Zhang P.  Zhang L.  Osman H.  Mohler E.R. 3rd  Macphee C.  Zalewski A.  Postle A.  Wilensky R.L.   Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses Atherosclerosis 2007 191 54 62 10.1016/j.atherosclerosis.2006.05.001 16765356 
93. Li B.  Dong Z.  Liu H.  Xia Y.F.  Liu X.M.  Luo B.B.  Wang W.K.  Li B.  Gao F.  Zhang C.    Serum amyloid A stimulates lipoprotein-associated phospholipase A2 expression in vitro and in vivo Atherosclerosis 2013 228 370 379 10.1016/j.atherosclerosis.2013.03.023 23623642 
94. Wang G.  Ji Y.  Li Z.  Han X.  Guo N.  Song Q.  Quan L.  Wang T.  Han W.  Pang D.    Nitro-oleic acid downregulates lipoprotein-associated phospholipase A2 expression via the p42/p44 MAPK and NFkappaB pathways Sci. Rep. 2014 4 4905 10.1038/srep04905 24809325 
95. Li D.  Wei W.  Ran X.  Yu J.  Li H.  Zhao L.  Zeng H.  Cao Y.  Zeng Z.  Wan Z.   Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis Clin. Chim. Acta 2017 471 38 45 10.1016/j.cca.2017.05.017 28514697 
96. Esenwa C.C.  Elkind M.S.   Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke Nat. Rev. Neurol. 2016 12 594 604 10.1038/nrneurol.2016.125 27615422 
97. Talmud P.J.  Holmes M.V.   Deciphering the causal role of sPLA2s and Lp-PLA2 in coronaryheart disease Arterioscler. Thromb. Vasc. Biol. 2015 35 2281 2289 10.1161/ATVBAHA.115.305234 26338298 
98. Chen J.  Zhang H.  Chen W.   Chemiluminescence immunoassay for sensing lipoprotein-associated phospholipase A2 in cardiovascular risk evaluation Clin. Chim. Acta 2019 488 143 149 10.1016/j.cca.2018.11.013 30414434 
99. Lu J.  Niu D.  Zheng D.  Zhang Q.  Li W.   Predictive value of combining the level of lipoprotein-associated phospholipase A2 and antithrombin III for acute coronary syndrome risk Biomed. Rep. 2018 9 517 522 10.3892/br.2018.1162 30546880 
100. Lyngbakken M.N.  Myhre P.L.  Rosjo H.  Omland T.   Novel biomarkers of cardiovascular disease: Applications in clinical practice Crit. Rev. Clin. Lab. Sci. 2018 56 33 60 10.1080/10408363.2018.1525335 30457415 
101. Zhou F.  Liu Y.  Shi H.  Huang Q.  Zhou J.   Relation between lipoprotein-associated phospholipase A2 mass and incident ischemic stroke severity Neurol. Sci. 2018 39 1591 1596 10.1007/s10072-018-3474-3 29938341 
102. Wang Y.  Hu S.  Ren L.  Lei Z.  Lan T.  Cai J.  Li C.   Lp-PLA2 as a risk factor of early neurological deterioration in acute ischemic stroke with TOAST type of large arterial atherosclerosis Neurol Res. 2018 1 8 10.1080/01616412.2018.1493850 30296199 
103. Ding C.Y.  Cai H.P.  Ge H.L.  Yu L.H.  Lin Y.X.  Kang D.Z.   Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage J. Neurosurg. 2019 10.3171/2018.8.JNS181839 30660116 
104. Wilensky R.L.  Shi Y.  Mohler E.R. 3rd  Hamamdzic D.  Burgert M.E.  Li J.  Postle A.  Fenning R.S.  Bollinger J.G.  Hoffman B.E.    Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development Nat. Med. 2008 14 1059 1066 10.1038/nm.1870 18806801 
105. Serruys P.W.  Garcia-Garcia H.M.  Buszman P.  Erne P.  Verheye S.  Aschermann M.  Duckers H.  Bleie O.  Dudek D.  Botker H.E.    Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque Circulation 2008 118 1172 1182 10.1161/CIRCULATIONAHA.108.771899 18765397 
106. Chen C.H.   Platelet-activating factor acetylhydrolase: Is it good or bad for you? Curr. Opin. Lipidol. 2004 15 337 341 10.1097/00041433-200406000-00015 15166791 
107. Marathe G.K.  Pandit C.  Lakshmikanth C.L.  Chaithra V.H.  Jacob S.P.  D’Souza C.J.   To hydrolyze or not to hydrolyze: The dilemma of platelet-activating factor acetylhydrolase J. Lipid Res. 2014 55 1847 1854 10.1194/jlr.R045492 24859738 
108. Benitez S.  Camacho M.  Arcelus R.  Vila L.  Bancells C.  Ordonez-Llanos J.  Sanchez-Quesada J.L.   Increased lysophosphatidylcholine and non-esterified fatty acid content in LDL induces chemokine release in endothelial cells. Relationship with electronegative LDL Atherosclerosis 2004 177 299 305 15530903 
109. Zhang H.  Zhou W.  Cao C.  Zhang W.  Liu G.  Zhang J.   Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40 PLoS ONE 2018 13 e0202797 10.1371/journal.pone.0202797 30138439 
110. Jonas A.   Regulation of lecithin cholesterol acyltransferase activity Prog. Lipid Res. 1998 37 209 234 10.1016/S0163-7827(98)00007-1 10193526 
111. Calabresi L.  Simonelli S.  Gomaraschi M.  Franceschini G.   Genetic lecithin:cholesterol acyltransferase deficiency and cardiovascular disease Atherosclerosis 2012 222 299 306 10.1016/j.atherosclerosis.2011.11.034 22189200 
112. Hirsch-Reinshagen V.  Donkin J.  Stukas S.  Chan J.  Wilkinson A.  Fan J.  Parks J.S.  Kuivenhoven J.A.  Lutjohann D.  Pritchard H.    LCAT synthesized by primary astrocytes esterifies cholesterol on glia-derived lipoproteins J. Lipid Res. 2009 50 885 893 10.1194/jlr.M800584-JLR200 19065001 
113. Calabresi L.  Franceschini G.   Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans Trends Cardiovasc. Med. 2010 20 50 53 10.1016/j.tcm.2010.03.007 20656215 
114. Kunnen S.  Van Eck M.   Lecithin:cholesterol acyltransferase: Old friend or foe in atherosclerosis? J. Lipid Res. 2012 53 1783 1799 10.1194/jlr.R024513 22566575 
115. Ossoli A.  Simonelli S.  Vitali C.  Franceschini G.  Calabresi L.   Role of LCAT in Atherosclerosis J. Atheroscler. Thromb. 2016 23 119 127 10.5551/jat.32854 26607351 
116. Oldoni F.  Baldassarre D.  Castelnuovo S.  Ossoli A.  Amato M.  van Capelleveen J.  Hovingh G.K.  De Groot E.  Bochem A.  Simonelli S.    Complete and partial lecithin: Cholesterol acyltransferase deficiency is differentially associated with atherosclerosis Circulation 2018 138 1000 1007 10.1161/CIRCULATIONAHA.118.034706 29748187 
117. Vargas-Alarcon G.  Perez-Mendez O.  Herrera-Maya G.  Garcia-Sanchez C.  Martinez-Rios M.A.  Pena-Duque M.A.  Posadas-Sanchez R.  Posadas-Romero C.  Escobedo G.  Fragoso J.M.   CETP and LCAT Gene Polymorphisms Are Associated with High-Density Lipoprotein Subclasses and Acute Coronary Syndrome Lipids 2018 53 157 166 10.1002/lipd.12017 29570220 
118. Asztalos B.F.  Schaefer E.J.  Horvath K.V.  Yamashita S.  Miller M.  Franceschini G.  Calabresi L.   Role of LCAT in HDL remodeling: Investigation of LCAT deficiency states J. Lipid Res. 2007 48 592 599 10.1194/jlr.M600403-JLR200 17183024 
119. Calabresi L.  Baldassarre D.  Simonelli S.  Gomaraschi M.  Amato M.  Castelnuovo S.  Frigerio B.  Ravani A.  Sansaro D.  Kauhanen J.    Plasma lecithin:cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk J. Lipid Res. 2011 52 1569 1574 10.1194/jlr.P014977 21596929 
120. Dullaart R.P.  Tietge U.J.  Kwakernaak A.J.  Dikkeschei B.D.  Perton F.  Tio R.A.   Alterations in plasma lecithin:cholesterol acyltransferase and myeloperoxidase in acute myocardial infarction: Implications for cardiac outcome Atherosclerosis 2014 234 185 192 10.1016/j.atherosclerosis.2014.02.026 24661908 
121. Dullaart R.P.  Perton F.  Sluiter W.J.  de Vries R.  van Tol A.   Plasma lecithin: Cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness J. Clin. Endocrinol. Metab. 2008 93 4860 4866 10.1210/jc.2008-1213 18782872 
122. Dong Z.  Shi H.  Zhao M.  Zhang X.  Huang W.  Wang Y.  Zheng L.  Xian X.  Liu G.   Loss of LCAT activity in the golden Syrian hamster elicits pro-atherogenic dyslipidemia and enhanced atherosclerosis Metabolism 2018 83 245 255 10.1016/j.metabol.2018.03.003 29526535 
123. Simonelli S.  Ossoli A.  Banfi C.  Pavanello C.  Calabresi L.  Gianazza E.   A proteomic approach to identify novel disease biomarkers in LCAT deficiency J. Proteom. 2018 10.1016/j.jprot.2018.12.005 30529744 
124. Furbee J.W. Jr.  Parks J.S.   Transgenic overexpression of human lecithin: Cholesterol acyltransferase (LCAT) in mice does not increase aortic cholesterol deposition Atherosclerosis 2002 165 89 100 10.1016/S0021-9150(02)00201-0 12208474 
125. Vaisman B.L.  Klein H.G.  Rouis M.  Berard A.M.  Kindt M.R.  Talley G.D.  Meyn S.M.  Hoyt R.F. Jr.  Marcovina S.M.  Albers J.J.    Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice J. Biol. Chem. 1995 270 12269 12275 10.1074/jbc.270.20.12269 7744879 
126. Nass K.J.  van den Berg E.H.  Gruppen E.G.  Dullaart R.P.F.   Plasma lecithin:cholesterol acyltransferase and phospholipid transfer protein activity independently associate with nonalcoholic fatty liver disease Eur J. Clin. Investig. 2018 48 e12988 10.1111/eci.12988 29947103 
127. Yokoyama K.  Tani S.  Matsuo R.  Matsumoto N.   Association of lecithin-cholesterol acyltransferase activity and low-density lipoprotein heterogeneity with atherosclerotic cardiovascular disease risk: A longitudinal pilot study BMC Cardiovasc. Disord. 2018 18 224 10.1186/s12872-018-0967-1 30518338 
128. Gebhard C.  Rhainds D.  He G.  Rodes-Cabau J.  Lavi S.  Spence J.D.  Title L.  Kouz S.  L’Allier P.L.  Gregoire J.    Elevated level of lecithin:cholesterol acyltransferase (LCAT) is associated with reduced coronary atheroma burden Atherosclerosis 2018 276 131 139 10.1016/j.atherosclerosis.2018.07.025 30059844 
129. Chen Z.  Chu D.  Castro-Perez J.M.  Ni W.  Zhang A.  Krsmanovic M.L.  Xie D.  Shah V.  Stout S.J.  McLaren D.G.    AAV8-mediated long-term expression of human LCAT significantly improves lipid profiles in hCETP;Ldlr(+/−) mice J. Cardiovasc. Transl. Res. 2011 4 801 810 10.1007/s12265-011-9309-8 21822774 
130. Silva-Filho A.F.  Sena W.L.B.  Lima L.R.A.  Carvalho L.V.N.  Pereira M.C.  Santos L.G.S.  Santos R.V.C.  Tavares L.B.  Pitta M.G.R.  Rego M.   Glycobiology Modifications in Intratumoral Hypoxia: The Breathless Side of Glycans Interaction Cell. Physiol. Biochem. 2017 41 1801 1829 10.1159/000471912 28376491 
131. Lu H.  Forbes R.A.  Verma A.   Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis J. Biol. Chem. 2002 277 23111 23115 10.1074/jbc.M202487200 11943784 
132. Li J.  Thorne L.N.  Punjabi N.M.  Sun C.K.  Schwartz A.R.  Smith P.L.  Marino R.L.  Rodriguez A.  Hubbard W.C.  O’Donnell C.P.    Intermittent hypoxia induces hyperlipidemia in lean mice Circ. Res. 2005 97 698 706 10.1161/01.RES.0000183879.60089.a9 16123334 
133. Trzepizur W.  Le Vaillant M.  Meslier N.  Pigeanne T.  Masson P.  Humeau M.P.  Bizieux-Thaminy A.  Goupil F.  Chollet S.  Ducluzeau P.H.    Independent association between nocturnal intermittent hypoxemia and metabolic dyslipidemia Chest 2013 143 1584 1589 10.1378/chest.12-1652 23699812 
134. Guo X.  Shang J.  Deng Y.  Yuan X.  Zhu D.  Liu H.   Alterations in left ventricular function during intermittent hypoxia: Possible involvement of O-GlcNAc protein and MAPK signaling Int. J. Mol. Med. 2015 36 150 158 10.3892/ijmm.2015.2198 25936416 
135. Yu Y.  Vidalino L.  Anesi A.  Macchi P.  Guella G.   A lipidomics investigation of the induced hypoxia stress on HeLa cells by using MS and NMR techniques Mol. Biosyst. 2014 10 878 890 10.1039/C3MB70540D 24496110 
136. Kamphorst J.J.  Cross J.R.  Fan J.  de Stanchina E.  Mathew R.  White E.P.  Thompson C.B.  Rabinowitz J.D.   Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids Proc. Natl. Acad. Sci. USA 2013 110 8882 8887 10.1073/pnas.1307237110 23671091 
137. Granger M.W.  Liu H.  Fowler C.F.  Blanchard A.P.  Taylor M.W.  Sherman S.P.M.  Xu H.  Le W.  Bennett S.A.L.   Distinct disruptions in Land’s cycle remodeling of glycerophosphocholines in murine cortex mark symptomatic onset and progression in two Alzheimer’s disease mouse models J. Neurochem. 2018 10.1111/jnc.14560 30040874 
138. Ojala P.J.  Hermansson M.  Tolvanen M.  Polvinen K.  Hirvonen T.  Impola U.  Jauhiainen M.  Somerharju P.  Parkkinen J.   Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: A complementary role to albumin in the scavenging of lysophosphatidylcholine Biochemistry 2006 45 14021 14031 10.1021/bi061657l 17115697 
139. Spanner S.  Ansell G.B.   Phospholipid transport and turnover in nervous tissue Biochem. Soc. Trans. 1979 7 338 341 10.1042/bst0070338 218859 
140. Takeshita S.  Inoue N.  Gao D.  Rikitake Y.  Kawashima S.  Tawa R.  Sakurai H.  Yokoyama M.   Lysophosphatidylcholine enhances superoxide anions production via endothelial NADH/NADPH oxidase J. Atheroscler. Thromb. 2000 7 238 246 10.5551/jat1994.7.238 11521688 
141. Uchida Y.  Uchida Y.  Kameda N.   Visualization of lipid components in human coronary plaques using color fluorescence angioscopy Circ. J. 2010 74 2181 2186 10.1253/circj.CJ-10-0451 20736502 
142. Switzer S.  Eder H.A.   Transport of lysolecithin by albumin in human and rat plasma J. Lipid Res. 1965 6 506 511 5865378 
143. Kugiyama K.  Sakamoto T.  Misumi I.  Sugiyama S.  Ohgushi M.  Ogawa H.  Horiguchi M.  Yasue H.   Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells Circ. Res. 1993 73 335 343 10.1161/01.RES.73.2.335 8330376 
144. Vuong T.D.  Stroes E.S.  Willekes-Koolschijn N.  Rabelink T.J.  Koomans H.A.  Joles J.A.   Hypoalbuminemia increases lysophosphatidylcholine in low-density lipoprotein of normocholesterolemic subjects Kidney Int. 1999 55 1005 1010 10.1046/j.1523-1755.1999.0550031005.x 10027937 
145. Stroes E.S.  Joles J.A.  Chang P.C.  Koomans H.A.  Rabelink T.J.   Impaired endothelial function in patients with nephrotic range proteinuria Kidney Int. 1995 48 544 550 10.1038/ki.1995.325 7564124 
146. Vuong T.D.  de Kimpe S.  de Roos R.  Rabelink T.J.  Koomans H.A.  Joles J.A.   Albumin restores lysophosphatidylcholine-induced inhibition of vasodilation in rat aorta Kidney Int. 2001 60 1088 1096 10.1046/j.1523-1755.2001.0600031088.x 11532104 
147. Vuong T.D.  Braam B.  Willekes-Koolschijn N.  Boer P.  Koomans H.A.  Joles J.A.   Hypoalbuminaemia enhances the renal vasoconstrictor effect of lysophosphatidylcholine Nephrol. Dial. Transpl. 2003 18 1485 1492 10.1093/ndt/gfg238 
148. Van Molle W.  Libert C.  Fiers W.  Brouckaert P.   Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice J. Immunol. 1997 159 3555 3564 9317155 
149. Lopez-Marques R.L.  Theorin L.  Palmgren M.G.  Pomorski T.G.   P4-ATPases: Lipid flippases in cell membranes Pflug. Arch. 2014 466 1227 1240 10.1007/s00424-013-1363-4 24077738 
150. Andersen J.P.  Vestergaard A.L.  Mikkelsen S.A.  Mogensen L.S.  Chalat M.  Molday R.S.   P4-ATPases as Phospholipid Flippases-Structure, Function, and Enigmas Front. Physiol. 2016 7 275 10.3389/fphys.2016.00275 27458383 
151. Linsel-Nitschke P.  Jehle A.W.  Shan J.  Cao G.  Bacic D.  Lan D.  Wang N.  Tall A.R.   Potential role of ABCA7 in cellular lipid efflux to apoA-I J. Lipid Res. 2005 46 86 92 10.1194/jlr.M400247-JLR200 15520449 
152. Abe-Dohmae S.  Ikeda Y.  Matsuo M.  Hayashi M.  Okuhira K.  Ueda K.  Yokoyama S.   Human ABCA7 supports apolipoprotein-mediated release of cellular cholesterol and phospholipid to generate high density lipoprotein J. Biol. Chem. 2004 279 604 611 10.1074/jbc.M309888200 14570867 
153. Tomioka M.  Toda Y.  Manucat N.B.  Akatsu H.  Fukumoto M.  Kono N.  Arai H.  Kioka N.  Ueda K.   Lysophosphatidylcholine export by human ABCA7 Biochim. Biophys. Acta 2017 1862 658 665 10.1016/j.bbalip.2017.03.012 28373057 
154. Aikawa T.  Holm M.L.  Kanekiyo T.   ABCA7 and Pathogenic Pathways of Alzheimer’s Disease Brain Sci. 2018 8 27 10.3390/brainsci8020027 29401741 
155. Qin Z.X.  Zhu H.Y.  Hu Y.H.   Effects of lysophosphatidylcholine on beta-amyloid-induced neuronal apoptosis Acta Pharmacol. Sin. 2009 30 388 395 10.1038/aps.2009.25 19343059 
156. Serna J.  Garcia-Seisdedos D.  Alcazar A.  Lasuncion M.A.  Busto R.  Pastor O.   Quantitative lipidomic analysis of plasma and plasma lipoproteins using MALDI-TOF mass spectrometry Chem. Phys. Lipids 2015 189 7 18 10.1016/j.chemphyslip.2015.05.005 26004846 
157. Holcapek M.  Cifkova E.  Cervena B.  Lisa M.  Vostalova J.  Galuszka J.   Determination of nonpolar and polar lipid classes in human plasma, erythrocytes and plasma lipoprotein fractions using ultrahigh-performance liquid chromatography-mass spectrometry J. Chromatogr. A 2015 1377 85 91 10.1016/j.chroma.2014.12.023 25543301 
158. Heermeier K.  Schneider R.  Heinloth A.  Wanner C.  Dimmeler S.  Galle J.   Oxidative stress mediates apoptosis induced by oxidized low-density lipoprotein and oxidized lipoprotein(a) Kidney Int. 1999 56 1310 1312 10.1046/j.1523-1755.1999.00685.x 10504482 
159. Perrin-Cocon L.  Diaz O.  Andre P.  Lotteau V.   Modified lipoproteins provide lipids that modulate dendritic cell immune function Biochimie 2013 95 103 108 10.1016/j.biochi.2012.08.006 22959067 
160. Coutant F.  Perrin-Cocon L.  Agaugue S.  Delair T.  Andre P.  Lotteau V.   Mature dendritic cell generation promoted by lysophosphatidylcholine J. Immunol. 2002 169 1688 1695 10.4049/jimmunol.169.4.1688 12165488 
161. Liang G.H.  Park S.  Kim M.Y.  Kim J.A.  Choi S.  Suh S.H.   Modulation of nonselective cation current by oxidized LDL and lysophosphatidylcholine and its inhibitory contribution to endothelial damage Life Sci. 2010 86 733 739 10.1016/j.lfs.2010.03.005 20226792 
162. Bao L.  Qi J.  Wang Y.W.  Xi Q.  Tserennadmid T.  Zhao P.F.  Qi J.  Damirin A.   The atherogenic actions of LPC on vascular smooth muscle cells and its LPA receptor mediated mechanism Biochem. Biophys. Res. Commun. 2018 503 1911 1918 10.1016/j.bbrc.2018.07.135 30064908 
163. Tselmin S.  Schmitz G.  Julius U.  Bornstein S.R.  Barthel A.  Graessler J.   Acute effects of lipid apheresis on human serum lipidome Atheroscler. Suppl. 2009 10 27 33 10.1016/S1567-5688(09)71806-9 20129370 
164. Soupene E.  Fyrst H.  Kuypers F.A.   Mammalian acyl-CoA:lysophosphatidylcholine acyltransferase enzymes Proc. Natl. Acad. Sci. USA 2008 105 88 93 10.1073/pnas.0709737104 18156367 
165. Singh A.B.  Liu J.   Identification of Hepatic Lysophosphatidylcholine Acyltransferase 3 as a Novel Target Gene Regulated by Peroxisome Proliferator-activated Receptor delta J. Biol. Chem. 2017 292 884 897 10.1074/jbc.M116.743575 27913621 
166. Shindou H.  Shimizu T.   Acyl-CoA:lysophospholipid acyltransferases J. Biol. Chem. 2009 284 1 5 10.1074/jbc.R800046200 18718904 
167. Morita Y.  Sakaguchi T.  Ikegami K.  Goto-Inoue N.  Hayasaka T.  Hang V.T.  Tanaka H.  Harada T.  Shibasaki Y.  Suzuki A.    Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression J. Hepatol. 2013 59 292 299 10.1016/j.jhep.2013.02.030 23567080 
168. Shida-Sakazume T.  Endo-Sakamoto Y.  Unozawa M.  Fukumoto C.  Shimada K.  Kasamatsu A.  Ogawara K.  Yokoe H.  Shiiba M.  Tanzawa H.    Lysophosphatidylcholine acyltransferase1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of platelet-activating factor PLoS ONE 2015 10 e0120143 10.1371/journal.pone.0120143 25803864 
169. Abdelzaher E.  Mostafa M.F.   Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence Tumour Biol. 2015 36 5473 5483 10.1007/s13277-015-3214-8 25683484 
170. Uehara T.  Kikuchi H.  Miyazaki S.  Iino I.  Setoguchi T.  Hiramatsu Y.  Ohta M.  Kamiya K.  Morita Y.  Tanaka H.    Overexpression of lysophosphatidylcholine acyltransferase 1 and concomitant lipid alterations in gastric cancer Ann. Surg. Oncol. 2016 23 Suppl. 2 S206 S213 10.1245/s10434-015-4459-6 25752890 
171. Mansilla F.  da Costa K.A.  Wang S.  Kruhoffer M.  Lewin T.M.  Orntoft T.F.  Coleman R.A.  Birkenkamp-Demtroder K.   Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer J. Mol. Med. (Berl.) 2009 87 85 97 10.1007/s00109-008-0409-0 18974965 
172. Cotte A.K.  Aires V.  Fredon M.  Limagne E.  Derangere V.  Thibaudin M.  Humblin E.  Scagliarini A.  de Barros J.P.  Hillon P.    Lysophosphatidylcholine acyltransferase 2-mediated lipid droplet production supports colorectal cancer chemoresistance Nat. Commun. 2018 9 322 10.1038/s41467-017-02732-5 29358673 
173. Agarwal A.K.  Garg A.   Enzymatic activity of the human 1-acylglycerol-3-phosphate-O-acyltransferase isoform 11: Upregulated in breast and cervical cancers J. Lipid Res. 2010 51 2143 2152 10.1194/jlr.M004762 20363836 
174. Li Z.  Ding T.  Pan X.  Li Y.  Li R.  Sanders P.E.  Kuo M.S.  Hussain M.M.  Cao G.  Jiang X.C.   Lysophosphatidylcholine acyltransferase 3 knockdown-mediated liver lysophosphatidylcholine accumulation promotes very low density lipoprotein production by enhancing microsomal triglyceride transfer protein expression J. Biol. Chem. 2012 287 20122 20131 10.1074/jbc.M111.334664 22511767 
175. Li Z.  Jiang H.  Ding T.  Lou C.  Bui H.H.  Kuo M.S.  Jiang X.C.   Deficiency in lysophosphatidylcholine acyltransferase 3 reduces plasma levels of lipids by reducing lipid absorption in mice Gastroenterology 2015 149 1519 1529 10.1053/j.gastro.2015.07.012 26226572 
176. Cao J.  Shan D.  Revett T.  Li D.  Wu L.  Liu W.  Tobin J.F.  Gimeno R.E.   Molecular identification of a novel mammalian brain isoform of acyl-CoA:lysophospholipid acyltransferase with prominent ethanolamine lysophospholipid acylating activity, LPEAT2 J. Biol. Chem. 2008 283 19049 19057 10.1074/jbc.M800364200 18458083 
177. Kurabe N.  Hayasaka T.  Ogawa M.  Masaki N.  Ide Y.  Waki M.  Nakamura T.  Kurachi K.  Kahyo T.  Shinmura K.    Accumulated phosphatidylcholine (16:0/16:1) in human colorectal cancer; possible involvement of LPCAT4 Cancer Sci. 2013 104 1295 1302 10.1111/cas.12221 23815430 
178. Tanaka N.  Matsubara T.  Krausz K.W.  Patterson A.D.  Gonzalez F.J.   Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis Hepatology 2012 56 118 129 10.1002/hep.25630 22290395 
179. Matsubara T.  Tanaka N.  Sato M.  Kang D.W.  Krausz K.W.  Flanders K.C.  Ikeda K.  Luecke H.  Wakefield L.M.  Gonzalez F.J.   TGF-beta-SMAD3 signaling mediates hepatic bile acid and phospholipid metabolism following lithocholic acid-induced liver injury J. Lipid Res. 2012 53 2698 2707 10.1194/jlr.M031773 23034213 
180. Xu S.  Zhao L.  Larsson A.  Venge P.   The identification of a phospholipase B precursor in human neutrophils FEBS J. 2009 276 175 186 10.1111/j.1742-4658.2008.06771.x 19019078 
181. Dor P.J.  Ackerman S.J.  Gleich G.J.   Charcot-Leyden crystal protein and eosinophil granule major basic protein in sputum of patients with respiratory diseases Am. Rev. Respir. Dis. 1984 130 1072 1077 10.1016/0091-6749(83)90220-8 6508005 
182. Ackerman S.J.  Weil G.J.  Gleich G.J.   Formation of Charcot-Leyden crystals by human basophils J. Exp. Med. 1982 155 1597 1609 10.1084/jem.155.6.1597 7042896 
183. Weller P.F.  Goetzl E.J.  Austen K.F.   Identification of human eosinophil lysophospholipase as the constituent of Charcot-Leyden crystals Proc. Natl. Acad. Sci. USA 1980 77 7440 7443 10.1073/pnas.77.12.7440 6261258 
184. Ackerman S.J.  Liu L.  Kwatia M.A.  Savage M.P.  Leonidas D.D.  Swaminathan G.J.  Acharya K.R.   Charcot-Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion J. Biol. Chem. 2002 277 14859 14868 10.1074/jbc.M200221200 11834744 
185. Holtsberg F.W.  Ozgur L.E.  Garsetti D.E.  Myers J.  Egan R.W.  Clark M.A.   Presence in human eosinophils of a lysophospholipase similar to that found in the pancreas Biochem. J. 1995 309 (Pt 1) 141 144 10.1042/bj3090141 7619049 
186. Su J.   A Brief History of Charcot-Leyden Crystal Protein/Galectin-10 Research Molecules 2018 23 2931 10.3390/molecules23112931 
187. Adamski M.G.  Li Y.  Wagner E.  Yu H.  Seales-Bailey C.  Soper S.A.  Murphy M.  Baird A.E.   Expression profile based gene clusters for ischemic stroke detection Genomics 2014 104 163 169 10.1016/j.ygeno.2014.08.004 25135788 
188. Moore D.F.  Li H.  Jeffries N.  Wright V.  Cooper R.A. Jr.  Elkahloun A.  Gelderman M.P.  Zudaire E.  Blevins G.  Yu H.    Using peripheral blood mononuclear cells to determine a gene expression profile of acute ischemic stroke: A pilot investigation Circulation 2005 111 212 221 10.1161/01.CIR.0000152105.79665.C6 15630028 
189. Wang A.  Yang H.C.  Friedman P.  Johnson C.A.  Dennis E.A.   A specific human lysophospholipase: cDNA cloning, tissue distribution and kinetic characterization Biochim. Biophys. Acta 1999 1437 157 169 10.1016/S1388-1981(99)00012-8 10064899 
190. Hirano T.  Kishi M.  Sugimoto H.  Taguchi R.  Obinata H.  Ohshima N.  Tatei K.  Izumi T.   Thioesterase activity and subcellular localization of acylprotein thioesterase 1/lysophospholipase 1 Biochim. Biophys. Acta 2009 1791 797 805 10.1016/j.bbalip.2009.05.001 19439193 
191. Kong E.  Peng S.  Chandra G.  Sarkar C.  Zhang Z.  Bagh M.B.  Mukherjee A.B.   Dynamic palmitoylation links cytosol-membrane shuttling of acyl-protein thioesterase-1 and acyl-protein thioesterase-2 with that of proto-oncogene H-ras product and growth-associated protein-43 J. Biol. Chem. 2013 288 9112 9125 10.1074/jbc.M112.421073 23396970 
192. Dekker F.J.  Rocks O.  Vartak N.  Menninger S.  Hedberg C.  Balamurugan R.  Wetzel S.  Renner S.  Gerauer M.  Scholermann B.    Small-molecule inhibition of APT1 affects Ras localization and signaling Nat. Chem. Biol. 2010 6 449 456 10.1038/nchembio.362 20418879 
193. Tian L.  McClafferty H.  Knaus H.G.  Ruth P.  Shipston M.J.   Distinct acyl protein transferases and thioesterases control surface expression of calcium-activated potassium channels J. Biol. Chem. 2012 287 14718 14725 10.1074/jbc.M111.335547 22399288 
194. Abrami L.  Dallavilla T.  Sandoz P.A.  Demir M.  Kunz B.  Savoglidis G.  Hatzimanikatis V.  van der Goot F.G.   Identification and dynamics of the human ZDHHC16-ZDHHC6 palmitoylation cascade Elife 2017 6 e27826 10.7554/eLife.27826 28826475 
195. Benesch M.G.  Ko Y.M.  McMullen T.P.  Brindley D.N.   Autotaxin in the crosshairs: Taking aim at cancer and other inflammatory conditions FEBS Lett. 2014 588 2712 2727 10.1016/j.febslet.2014.02.009 24560789 
196. Nakamura K.  Takeuchi T.  Ohkawa R.  Okubo S.  Yokota H.  Tozuka M.  Aoki J.  Arai H.  Ikeda H.  Ohshima N.    Serum lysophospholipase D/autotaxin may be a new nutritional assessment marker: Study on prostate cancer patients Ann. Clin. Biochem. 2007 44 (Pt 6) 549 556 10.1258/000456307782268147 17961310 
197. Zimmermann H.  Zebisch M.  Strater N.   Cellular function and molecular structure of ecto-nucleotidases Purinergic Signal. 2012 8 437 502 10.1007/s11302-012-9309-4 22555564 
198. Perrakis A.  Moolenaar W.H.   Autotaxin: Structure-function and signaling J. Lipid Res. 2014 55 1010 1018 10.1194/jlr.R046391 24548887 
199. Stracke M.L.  Krutzsch H.C.  Unsworth E.J.  Arestad A.  Cioce V.  Schiffmann E.  Liotta L.A.   Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein J. Biol. Chem. 1992 267 2524 2529 1733949 
200. Tanaka M.  Okudaira S.  Kishi Y.  Ohkawa R.  Iseki S.  Ota M.  Noji S.  Yatomi Y.  Aoki J.  Arai H.   Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid J. Biol. Chem. 2006 281 25822 25830 10.1074/jbc.M605142200 16829511 
201. van Meeteren L.A.  Ruurs P.  Stortelers C.  Bouwman P.  van Rooijen M.A.  Pradere J.P.  Pettit T.R.  Wakelam M.J.  Saulnier-Blache J.S.  Mummery C.L.    Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development Mol. Cell. Biol. 2006 26 5015 5022 10.1128/MCB.02419-05 16782887 
202. Moolenaar W.H.  Houben A.J.  Lee S.J.  van Meeteren L.A.   Autotaxin in embryonic development Biochim. Biophys. Acta 2013 1831 13 19 10.1016/j.bbalip.2012.09.013 23022664 
203. Brindley D.N.   Lipid phosphate phosphatases and related proteins: Signaling functions in development, cell division, and cancer J. Cell. Biochem. 2004 92 900 912 10.1002/jcb.20126 15258914 
204. Liu S.  Umezu-Goto M.  Murph M.  Lu Y.  Liu W.  Zhang F.  Yu S.  Stephens L.C.  Cui X.  Murrow G.    Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases Cancer Cell 2009 15 539 550 10.1016/j.ccr.2009.03.027 19477432 
205. David M.  Wannecq E.  Descotes F.  Jansen S.  Deux B.  Ribeiro J.  Serre C.M.  Gres S.  Bendriss-Vermare N.  Bollen M.    Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts PLoS ONE 2010 5 e9741 10.1371/journal.pone.0009741 20305819 
206. Kehlen A.  Englert N.  Seifert A.  Klonisch T.  Dralle H.  Langner J.  Hoang-Vu C.   Expression, regulation and function of autotaxin in thyroid carcinomas Int. J. Cancer 2004 109 833 838 10.1002/ijc.20022 15027116 
207. Brindley D.N.  Lin F.T.  Tigyi G.J.   Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy Biochim. Biophys. Acta 2013 1831 74 85 10.1016/j.bbalip.2012.08.015 22954454 
208. Nakagawa H.  Ikeda H.  Nakamura K.  Ohkawa R.  Masuzaki R.  Tateishi R.  Yoshida H.  Watanabe N.  Tejima K.  Kume Y.    Autotaxin as a novel serum marker of liver fibrosis Clin. Chim. Acta 2011 412 1201 1206 10.1016/j.cca.2011.03.014 21419756 
209. Kaffe E.  Katsifa A.  Xylourgidis N.  Ninou I.  Zannikou M.  Harokopos V.  Foka P.  Dimitriadis A.  Evangelou K.  Moulas A.N.    Hepatocyte autotaxin expression promotes liver fibrosis and cancer Hepatology 2017 65 1369 1383 10.1002/hep.28973 27981605 
210. Nakamura K.  Kishimoto T.  Ohkawa R.  Okubo S.  Tozuka M.  Yokota H.  Ikeda H.  Ohshima N.  Mizuno K.  Yatomi Y.   Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma in vitro: Proposal of a plasma sample preparation method for laboratory testing of these lipids Anal. Biochem. 2007 367 20 27 10.1016/j.ab.2007.05.004 17568554 
211. Hosogaya S.  Yatomi Y.  Nakamura K.  Ohkawa R.  Okubo S.  Yokota H.  Ohta M.  Yamazaki H.  Koike T.  Ozaki Y.   Measurement of plasma lysophosphatidic acid concentration in healthy subjects: Strong correlation with lysophospholipase D activity Ann. Clin. Biochem. 2008 45 (Pt 4) 364 368 10.1258/acb.2008.007242 18583620 
212. Michalczyk A.  Budkowska M.  Dolegowska B.  Chlubek D.  Safranow K.   Lysophosphatidic acid plasma concentrations in healthy subjects: Circadian rhythm and associations with demographic, anthropometric and biochemical parameters Lipids Health Dis. 2017 16 140 10.1186/s12944-017-0536-0 28732508 
213. Fourcade O.  Simon M.F.  Viode C.  Rugani N.  Leballe F.  Ragab A.  Fournie B.  Sarda L.  Chap H.   Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells Cell 1995 80 919 927 10.1016/0092-8674(95)90295-3 7697722 
214. Aoki J.  Taira A.  Takanezawa Y.  Kishi Y.  Hama K.  Kishimoto T.  Mizuno K.  Saku K.  Taguchi R.  Arai H.   Serum lysophosphatidic acid is produced through diverse phospholipase pathways J. Biol. Chem. 2002 277 48737 48744 10.1074/jbc.M206812200 12354767 
215. Leblanc R.  Houssin A.  Peyruchaud O.   Platelets, autotaxin and lysophosphatidic acid signalling: Win-win factors for cancer metastasis Br. J. Pharmacol. 2018 175 3100 3110 10.1111/bph.14362 29777586 
216. Choi J.W.  Herr D.R.  Noguchi K.  Yung Y.C.  Lee C.W.  Mutoh T.  Lin M.E.  Teo S.T.  Park K.E.  Mosley A.N.    LPA receptors: Subtypes and biological actions Annu. Rev. Pharmacol. Toxicol. 2010 50 157 186 10.1146/annurev.pharmtox.010909.105753 20055701 
217. Knowlden S.  Georas S.N.   The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation J. Immunol. 2014 192 851 857 10.4049/jimmunol.1302831 24443508 
218. Hernandez-Araiza I.  Morales-Lazaro S.L.  Canul-Sanchez J.A.  Islas L.D.  Rosenbaum T.   The role of lysophosphatidic acid on ion channel function and disease J. Neurophysiol. 2018 120 1198 1211 10.1152/jn.00226.2018 29947596 
219. Kanda H.  Newton R.  Klein R.  Morita Y.  Gunn M.D.  Rosen S.D.   Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs Nat. Immunol. 2008 9 415 423 10.1038/ni1573 18327261 
220. Zhang Y.  Chen Y.C.  Krummel M.F.  Rosen S.D.   Autotaxin through lysophosphatidic acid stimulates polarization, motility, and transendothelial migration of naive T cells J. Immunol. 2012 189 3914 3924 10.4049/jimmunol.1201604 22962684 
221. D’Souza K.  Paramel G.V.  Kienesberger P.C.   Lysophosphatidic Acid Signaling in Obesity and Insulin Resistance Nutrients 2018 10 399 10.3390/nu10040399 
222. Navab M.  Chattopadhyay A.  Hough G.  Meriwether D.  Fogelman S.I.  Wagner A.C.  Grijalva V.  Su F.  Anantharamaiah G.M.  Hwang L.H.    Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis J. Lipid Res. 2015 56 871 887 10.1194/jlr.M056614 25646365 
223. Chen X.  Yang X.Y.  Wang N.D.  Ding C.  Yang Y.J.  You Z.J.  Su Q.  Chen J.H.   Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction Scand. J. Clin. Lab. Investig. 2003 63 497 503 10.1080/00365510310003265 14743959 
224. Chen L.  Zhang J.  Deng X.  Liu Y.  Yang X.  Wu Q.  Yu C.   Lysophosphatidic acid directly induces macrophage-derived foam cell formation by blocking the expression of SRBI Biochem. Biophys. Res. Commun. 2017 491 587 594 10.1016/j.bbrc.2017.07.159 28765047 
225. Zhou Z.B.  Yang B.  Li X.  Liu H.  Lei G.   Lysophosphatidic Acid Promotes Expression and Activation of Matrix Metalloproteinase 9 (MMP9) in THP-1 Cells via Toll-Like Receptor 4/Nuclear Factor-kappaB (TLR4/NF-kappaB) Signaling Pathway Med. Sci. Monit. 2018 24 4861 4868 10.12659/MSM.906450 30005060 
226. Kritikou E.  van Puijvelde G.H.  van der Heijden T.  van Santbrink P.J.  Swart M.  Schaftenaar F.H.  Kroner M.J.  Kuiper J.  Bot I.   Inhibition of lysophosphatidic acid receptors 1 and 3 attenuates atherosclerosis development in LDL-receptor deficient mice Sci. Rep. 2016 6 37585 10.1038/srep37585 27883026 
227. Aldi S.  Matic L.P.  Hamm G.  van Keulen D.  Tempel D.  Holmstrom K.  Szwajda A.  Nielsen B.S.  Emilsson V.  Ait-Belkacem R.    Integrated human evaluation of the lysophosphatidic acid pathway as a novel therapeutic target in atherosclerosis Mol. Ther. Methods Clin. Dev. 2018 10 17 28 10.1016/j.omtm.2018.05.003 30003117 
228. Chandra M.  Escalante-Alcalde D.  Bhuiyan M.S.  Orr A.W.  Kevil C.  Morris A.J.  Nam H.  Dominic P.  McCarthy K.J.  Miriyala S.    Cardiac-specific inactivation of LPP3 in mice leads to myocardial dysfunction and heart failure Redox. Biol. 2018 14 261 271 10.1016/j.redox.2017.09.015 28982073 
229. Hisano Y.  Hla T.   Bioactive lysolipids in cancer and angiogenesis Pharmacol. Ther. 2018 10.1016/j.pharmthera.2018.07.006 30048709 
230. Lee D.  Suh D.S.  Lee S.C.  Tigyi G.J.  Kim J.H.   Role of autotaxin in cancer stem cells Cancer Metastasis Rev. 2018 37 509 518 10.1007/s10555-018-9745-x 29926310 
231. Schmid R.  Wolf K.  Robering J.W.  Strauss S.  Strissel P.L.  Strick R.  Rubner M.  Fasching P.A.  Horch R.E.  Kremer A.E.    ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro BMC Cancer 2018 18 1273 10.1186/s12885-018-5166-z 30567518 
232. Mazzocca A.  Schonauer L.M.  De Nola R.  Lippolis A.  Marrano T.  Loverro M.  Sabba C.  Di Naro E.   Autotaxin is a novel molecular identifier of type I endometrial cancer Med. Oncol. 2018 35 157 10.1007/s12032-018-1222-4 30374843 
233. Tigyi G.J.  Yue J.  Norman D.D.  Szabo E.  Balogh A.  Balazs L.  Zhao G.  Lee S.C.   Regulation of tumor cell—Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis Adv. Biol. Regul. 2019 71 183 193 10.1016/j.jbior.2018.09.008 30243984 
234. Genc G.E.  Hipolito V.E.B.  Botelho R.J.  Gumuslu S.   Lysophosphatidic acid represses autophagy in prostate carcinoma cells Biochem. Cell Biol. 2018 10.1139/bcb-2018-0164 30403494 
235. Takahashi K.  Minami K.  Otagaki S.  Ishimoto K.  Fukushima K.  Fukushima N.  Honoki K.  Tsujiuchi T.   Lysophosphatidic acid receptor-2 (LPA2) and LPA5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells Biochem. Biophys. Res. Commun. 2018 503 2698 2703 10.1016/j.bbrc.2018.08.026 30093116 
236. Xu Y.   Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment Cancers 2018 10 227 10.3390/cancers10070227 29987226 
237. Takahashi K.  Fukushima K.  Tanaka K.  Minami K.  Ishimoto K.  Otagaki S.  Fukushima N.  Honoki K.  Tsujiuchi T.   Involvement of LPA signaling via LPA receptor-2 in the promotion of malignant properties in osteosarcoma cells Exp. Cell Res. 2018 369 316 324 10.1016/j.yexcr.2018.05.037 29859140 
238. Ramesh S.  Govindarajulu M.  Suppiramaniam V.  Moore T.  Dhanasekaran M.   Autotaxin(-)lysophosphatidic acid signaling in Alzheimer’s disease Int. J. Mol. Sci. 2018 19 1827 10.3390/ijms19071827 
239. Shi J.  Dong Y.  Cui M.Z.  Xu X.   Lysophosphatidic acid induces increased BACE1 expression and Abeta formation Biochim. Biophys. Acta 2013 1832 29 38 10.1016/j.bbadis.2012.09.010 23036978 
240. Zhang J.B.  Cong Y.N.  Li Z.G.  Sun H.R.  Zhang J.S.  Wang P.F.  Wu Q.Z.   Plasma Phospholipids are Associated with Mild Cognitive Impairment in Type 2 Diabetic Patients Curr. Alzheimer Res. 2017 14 592 597 10.2174/1567205013666161201200722 27915992

